Early mural cell dysfunction biomarkers

ULM is used to detect and monitor mural cell dysfunction through vascular and hemodynamic changes, addressing the resolution limitations of conventional imaging and enabling early diagnosis and personalized treatment.

WO2026238892A1PCT designated stage Publication Date: 2026-11-19ICONEUS +3
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/064085
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-14
Filing Date
2026-05-13
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Conventional imaging modalities lack the spatial and temporal resolution to detect early mural cell dysfunction, which often manifests as subtle vascular and hemodynamic changes in the brain, leading to delayed diagnosis and intervention in neurological diseases.

Method used

Utilizing Ultrasound Localization Microscopy (ULM) to detect and monitor vascular and hemodynamic phenotype changes in the arteriole zone and Arteriole-Capillary Transition (ACT) zone, assessing parameters such as vessel diameter, tortuosity, and blood flow to identify mural cell dysfunction and evaluate therapeutic responses.

Benefits of technology

Enables early detection and monitoring of mural cell dysfunction, facilitating timely intervention and personalized treatment strategies by providing high-resolution imaging of microvascular alterations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000063_0000
    Figure 00000063_0000
  • Figure 00000063_0001
    Figure 00000063_0001
  • Figure 00000063_0002
    Figure 00000063_0002
Patent Text Reader

Abstract

The present disclosure relates to non-invasive imaging methods for detecting early mural cell dysfunction. The technical problem addressed is the challenge of identifying early mural cell induced microvascular changes that are undetectable by conventional imaging techniques. This method allows for the detection of vascular and hemodynamic changes, which serve as early biomarkers of mural cell dysfunction. The primary use of this technology is in the early diagnosis and monitoring of neurological diseases, enabling timely intervention and evaluation of therapeutic responses.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] EARLY MURAL CELL DYSFUNCTION BIOMARKERS

[0002] TECHNICAL FIELD

[0003] The present disclosure pertains to non-invasive imaging methods for detecting and monitoring mural cell dysfunction, preferably associated with neurological diseases.

[0004] BACKGROUND

[0005] Mural cell dysfunction can lead to neurological diseases that commonly occur with aging. Diseases such as Alzheimer’s, stroke, and other neurodegenerative conditions are now understood to involve early alterations in the microvascular network and the disruption of blood-brain barrier integrity. In this context, vascular cells play a significant role in regulating cerebral blood flow and maintaining the delicate balance needed for proper brain function. As investigations into these processes progress, the need for advanced imaging approaches to monitor vascular changes non-invasively has emerged. Such imaging techniques are vital for gaining deeper insights into the early events that may trigger neurological disease and to inform more effective future interventions.

[0006] However, obtaining functional information on living organs non-invasively across different size scales is a tremendous challenge in clinical imaging, as cerebrovascular dysfunction starts locally and deep into the brain before expressing large-scale and observable symptoms.

[0007] Structural and functional changes of the microvasculature are often discrete and include increased blood capillary dilatation and tortuosity, variations in vessel density and changes in local blood flow and permeability (Armulik, A. et al. Nature 468, 557-561 (2010) , Berthiaume, A. A. et al. Nat Commun 13, 5912 (2022)).

[0008] Clinical imaging modalities such as Computed Tomography (CT), Magnetic Resonance, Angiography (MRA) or functional Magnetic Resonance Imaging (fMRI) are essential for the evaluation of patients with cerebrovascular pathologies but are restricted to tenths of millimetres in spatial resolution and thus fail to detect the vast majority of cerebral small vessels but also to quantify most blood flow dynamics. Consequently, the initial stages of mural celldysfunction may remain undetected until more pronounced and irreversible pathological changes occur, delaying timely clinical intervention.

[0009] Recent advancements in Ultrasound Localisation Microscopy (ULM) with the ability to detect the brain vasculature and function at microscopic resolution, have opened a complete paradigm shift in angiography (WO2023 / 156576).

[0010] A non-invasive imaging modality able to image microvascular alterations is today missing and the development of mural cell dysfunction-focused therapies remains challenging due to the lack of early biomarkers of disease progression.

[0011] A specific challenge lies in the precise characterization and continuous monitoring of significant vascular parameters, such as vessel tortuosity and subtle changes in hemodynamic flow, within vital brain regions. Areas that exhibit early dysregulation of vascular control mechanisms may serve as important indicators of disease progression, yet these features are often obscured by the limited resolution of conventional imaging tools.

[0012] A refined non-invasive approach capable of accurately delineating these changes would provide a much-needed tool for early intervention and more personalized treatment strategies. Addressing these challenges could pave the way for enhanced diagnostic capabilities and improved therapeutic outcomes in patients suffering from mural cell dysfunction, preferably neurological conditions associated with mural cell dysfunction.

[0013] SUMMARY

[0014] Mural cell dysfunction can result in dysregulation of cerebral blood flow and disruption of the blood-brain barrier, leading to brain damage, neurodegeneration and cognitive decline.

[0015] A specific challenge is the reliable detection of early mural cell dysfunction in specific zones. Such early vascular and hemodynamic changes are often too minute to be discerned by conventional imaging modalities, which typically require larger-scale structural differences to register abnormality.

[0016] In the present application, the inventors used Ultrasound Localization Microscopy (ULM) that offers high temporal and spatial resolution, to detect microvascular changes at a microscopic scale. They showed that this approach allows for the identification of early hemodynamic and vascular phenotype change (e.g., increased diameters, reduced blood speed in the arteriole zoneor the Arteriole-Capillary Transition (ACT) zone) which are indicative of mural cell dysfunction that can be associated with a neurological disease. The described technology further demonstrates the potential of ULM in monitoring the efficacy of focused therapies, such as the Transforming Growth factor-P signaling activator C381, or AKT inhibitor which can restore hemodynamic or vascular phenotype and neurovascular response. This technology makes it possible to evaluate early mural cell dysfunction, preferably mural cell dysfunction associated with neurological disease, and drug efficacy in humans, offering a significant advancement over traditional imaging techniques that lack the resolution to detect such early-stage microvascular changes.

[0017] The present disclosure relates to a non-invasive method for detecting or monitoring mural cell dysfunction, said method comprising: determining at least one vascular and / or at least one hemodynamic phenotype change in a region of interest in the arteriole zone or arteriolecapillary transition (ACT) zone, preferably in the brain, in a human subject compared to corresponding control value(s), preferably wherein said vascular and hemodynamic phenotype change is determined by comparing at least one vascular parameter value and / or at least one hemodynamic parameter value, previously measured in a region of interest in the arteriole zone or ACT zone with corresponding control value(s), and wherein said vascular is selected among vessel diameter, vessel length and vessel tortuosity and hemodynamic parameter values is selected among: blood velocity, blood flow, blood pressure and blood volume; wherein said at least one vascular and / or said least one hemodynamic phenotype change compared to corresponding control value(s) is indicative that the human subject is likely to have mural cell dysfunction. In a preferred embodiment, a higher vessel diameter, a higher vessel tortuosity or a lower blood velocity compared to corresponding control value in a region of interest in the arteriole zone or ACT zone of the brain is indicative that said subject has a mural dysfunction, preferably associated with a neurological disease, such as HHT or Retinal Vasculopathy with Cerebral Leukoencephalopathy and systemic manifestations (RVCL-S).

[0018] In another embodiment, the present disclosure relates to a non-invasive method for evaluating the therapeutic response to a therapeutic agent in a human subject suffering from a disease, preferably a neurological disease associated with mural cell dysfunction, comprising: determining at least one vascular and / or at least one hemodynamic phenotype change in a region of interest in the arteriole zone or ACT zone, preferably in the brain, in a human subject compared to corresponding control value(s), preferably wherein said vascular and hemodynamic phenotype change is determined by comparing at least one vascular parametervalue and / or at least one hemodynamic parameter value previously measured in a region of interest in the arteriole zone or ACT zone, with corresponding control value(s), and wherein said vascular is selected among vessel diameter, vessel length and vessel tortuosity and hemodynamic parameter values is selected among: blood velocity, blood flow, blood pressure and blood volume, wherein said at least one vascular and / or at least one hemodynamic phenotype change compared to corresponding control value(s), is indicative that the human subject having received at least one dose of therapeutic agent is likely responsive to said treatment. In a preferred embodiment, the therapeutic response is evaluated throughout the course of said treatment for monitoring the therapeutic response over time. In a more particular embodiment, said therapeutic agent is an anti-inflammatory drug, preferably selected among: anti-angiogenic agent such as Angiopoietin 2 inhibitor, VEGF inhibitor, Tyrosine kinase inhibitor, PI3K inhibitor, AKT inhibitor, mTor inhibitor, MEK1 / 2 inhibitor; anti-inflammatory agent, such as Non-steroidal anti-inflammatory drugs (NS AID), MAPK inhibitor, TNF inhibitor; mural cell targeting drug such as TGFP agonist or PDGF inhibitor; Immunomodulatory imide drugs (IMiDs) or Rho signalling inhibitor. In a more preferred embodiment, the therapeutic agent is a TGFP agonist, and a lower vessel tortuosity compared to corresponding control value(s), is indicative that the human subject is likely responsive to TGFP agonist treatment, or the therapeutic agent is a Akt inhibitor and a lower vessel tortuosity, lower vessel diameter and / or higher blood velocity compared to corresponding control value(s), is indicative that the human subject is likely responsive to Akt inhibitor treatment.

[0019] In a preferred embodiment of the methods described above, said vascular or hemodynamic parameter value is previously measured using Ultrasound Localization Microscopy (ULM) or functional ultrasound (fUS) imaging, and preferably wherein a contrast agent is previously administered to said human subject, preferably by bolus or infusion injection. In a particular embodiment, said control value is the vascular and / or hemodynamic phenotypes determined in a region of interest in the arteriole zone or ACT zone in the same human subject at a previous time, preferably in the same region of interest in the arteriole zone or ACT zone or a predetermined value.

[0020] In a more particular embodiment, said methods further comprising a step of determining a neurovascular coupling phenotype change by comparing at least one vascular or hemodynamic parameter value change, preferably blood volume change, in response to a nervous stimulus, previously measured in a region of interest in the arteriole zone or ACT zone in the human subject, with corresponding control value(s). In a preferred embodiment, the determination ofthe neurovascular coupling phenotype change, and the determination of the vascular and / or hemodynamic change are measured in a single acquisition step, preferably using ULM, more preferably using ULM and f(US) imaging.

[0021] The methods as described above are preferably computer-implemented methods, for example implemented by computer executing code instructions stored on a memory.

[0022] According to the present disclosure, said mural cell dysfunction may be associated with hereditary disease, preferably selected from the group consisting of: with hereditary disease, preferably selected from the group consisting of: Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), Cerebral Autosomal Recessive Arteriopathy with Subcortical infarcts and Leukoencephalopathy (CARASIL), HTRA1 -autosomal dominant disease, Col4-related autosomal disease such as Collagen 4 Al and collagen 4A2 microangiopathy, Cathepsin-A-related arteriopathy with strokes and leukoencephalopathy (CARASAL), Retinal Vasculopathy with Cerebral Leukoencephalopathy and systemic manifestations (RVCL-S), Hereditary Hemorrhagic Telangiectasia (HHT), Fabry’s disease, Mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS), Cerebral Amyloid Angiopathy (CAA), Homocystinuria recessive disease, Sickle Cell disease, Parkes Weber syndrome, and CM-AVM syndrome, more preferably Hereditary Hemorrhagic Telangiectasia (HHT) or wherein said mural cell dysfunction is associated with a non-genetic disease, preferably selected from the group consisting of: stroke, traumatic brain injury, migraine, epilepsy, spinal cord injury, diabetes, Huntington’s disease, Alzheimer’s disease, Parkinson’s disease, Radiation necrosis, Amyotrophic lateral sclerosis, Vascular dementia, and Wybur-Mason syndrome.

[0023] The present disclosure also relates to a therapeutic agent for use in the treatment of a disease, preferably a neurological disease associated with mural cell dysfunction in a human subject in need thereof wherein said subject is previously identified as having a mural cell dysfunction by the method as described above, or wherein said subject is previously evaluated as likely responsive to said therapeutic agent in the method as described above, preferably said therapeutic agent is an anti-angiogenic agent such as Angiopoietin 2 inhibitor, VEGF inhibitor, Tyrosine kinase inhibitor, PI3K inhibitor, AKT inhibitor, mTor inhibitor, MEK1 / 2 inhibitor; anti-inflammatory agent, such as Non-steroidal anti-inflammatory drugs (NS AID), MAPK inhibitor, TNF inhibitor ; mural cell targeting drug such as TGFP agonist or PDGF inhibitor; Immunomodulatory imide drugs (IMiDs) or Rho signalling inhibitor.DESCRIPTION OF THE FIGURES

[0024] Figure 1. Mural cell organization in Eng-iKCE mouse retinal and cerebral vasculature, (a) Schematic of mural cell populations along the arterial-capillary axis, (b) Confocal images of genetically labelled retinal ensheathing pericytes (EPs) and mesh pericytes (MPs) (NG2DdRedBAC transgenic mice) attached to endothelium (isolectin-B4) in control and Eng-iKOemice (scale bar: 50 pm). Higher magnification of EPs and MPs in boxes shown at right (scale bar: 10 pm), (c) Quantification of EP roundness and (d) capillary diameters in control (n=3, total pericytes = 67) vs Eng-iKOe(n=3 , total pericytes = 46) mice, (e) Quantification of MP roundness and (f) capillary diameters in control (n=3, total pericytes = 95) vs Eng-iKOe(n=3, total pericytes = 72) mice, (g) TEM image of a retinal vessel with a contractile pericyte in Eng-iKOe(scale bar: 2 pm), (h) Vascular segment with a contractile pericyte before, during and after electrical stimulation (scale bar : 20 pm), (i-j) proportion of EPs (i) and MPs (j) inducing vascular constriction at the indicated current (pA), and the mean current inducing EP and MP-mediated contraction in control (n=4, total EPs=14, MPs=16) and Eng-iKOe(n=4, total EPs=15, MPs=19) mice, (k) schematic of mural cells enwrapping penetrating arterioles across the cortex. (1) Representative confocal images of the post-arteriole transition zone of penetrating arterioles in control and Eng-iKOebrains (isolectin-B4 for endothelial cells, NG2 for pericytes, a-SMAfor SMCs (Smooth muscle cells) and EP) (scale bar: 50 pm). Higher magnification of contractile pericytes in boxes shown below. Arrows mark contractile pericytes (scale bar: 10 pm), (m) Quantification of pericyte roundness in control (n=3, total pericytes =70) and Eng-iKOe(n=3, total pericytes = 53) mice. Error bars show SEM. P value result from unpaired t-tests.

[0025] Figure 2: Ultrasound Localization microscopy reveals cerebral arteriole abnormalities in Eng-iKCE mice, (a) Normalized microbubbles (MB) count of ULM maps of the mouse brain vasculature in both control and Eng-iKOemice (scale bar: 1 mm), (b) Blood flow velocity of ULM maps of the mouse brain vasculature in both control and Eng-iKOemice (scale bar: 1 mm). A higher magnification image in the bow shows post-capillary small venules branching to an ascending venule and penetrating arterioles branching to post-arteriole transitional zone capillaries (sclae bar: 1 mm), (c-d) Longitudinal profiles and quantification of MB count (c) and velocity (d) along ascending venules (depth 0-1,400 pm of the cortex) during the resting period in a control mouse (nvenuie=7) and in an Eng-iKOemice (nvenuie=7). (e-f) Longitudinal profiles of MB counts (e) and velocity (f) along penetrating arterioles and quantification of MB flow and velocity along arterioles (depth 0-400 pm of the cortex) and post-arteriole transitionalblood vessels (depth 800-1,400 pm of the cortex) during the resting period in both a mouse control (narterioie=14 and nACT=10) and Eng-iKOemice (narterioie=18 and nACT=10). Error bars represent SEM. P values result from unpaired / -tests.

[0026] Figure 3: Analysis of the arteriolar architecture, (a) ULM backscattering imaging offering better blood vessel delineation than MB count (scale bar: 500 pm). Higher magnification images of the cortex in boxes are shown at the bottom (scale bar: 500 pm), (b) Quantification of arteriolar blood vessel diameter in a control mouse (nvessei = 25) and in an Eng-iKOemouse (nvessei = 25). (c) high magnification images of MB count maps showing vessel tortuosity (scale bar: 500 pm) in a control animal and in an Eng-iKOemouse, (d) Comparison of vessels tortuosity in a control animal (narterioie = 6) and in an Eng-iKOemouse (narterioie = 6) measured as the standard deviation of velocity vector scalar products along each vessel (scale bar: 500 pm), (e) High magnification images of MB count maps showing a helical buckling vascular structure in Eng-iKOemice (scale bar: 100 pm). Error bars represent SEM. P values result from unpaired / -tests.

[0027] Figure 4: Neurovascular uncoupling revealed by fUS. (a) Transcranial fUS imaging of task-induced changes in cerebral blood flow in the somatosensorial cortex during whisker stimulation in anaesthetized mice (scale bar: 1 mm), (b) Mean time-series of all trials of the activated region with grey boxes showing temporal correlation between the stimulus pattern and the haemodynamic response in both control (n = 6) and Eng-iKOe(n = 8) mice, (c) Baseline CBV values over time and quantification (d) Average of the haemodynamic response within a chosen region of interest, (e-g) Quantification of the increased response amplitude at early (e) (start to 10 s) and late (1) (from 10 to 30 s) excitation response, (g) Quantification of the rise time. All error bars represent SEM. P values result from unpaired t-tests.

[0028] Figure 5: Contractile pericyte dysfunction during the hyperaemic response revealed by functional Ultrasound Localization Microscopy, (a) Top left, MB count ULM map at bregma = -2 mm containing the barrel cortex. Bottom left, corresponding fULM activation map showing the activated region in the barrel cortex (scale bar: 1 mm). Top right, zoom in the fULM activation map showing the absence of hyperaemia before stimulation in the 24-28 s time window (scale bar: 500 pm). Dashed dotted white line corresponds to z=400 pm depth in the cortex. Bottom right, zoom in the fULM activation map during the stimulation (30-58 s), (scale bar: 500 pm), (b) Activation maps and MB tracks detected in 4 s temporal windows during stimulation, (scale bar: 500 pm), (c) Mean time-series of MB flow increase from 0 to400 m depth, (d-e) Quantification of the MB flow increase in early and late phase of the stimulation in control (n = 5) and Eng-iKOe(n = 8) mice, (f) Mean time-series of MB flow increase from 400 to 1,200 pm depth, (g-h) Quantification of the MB flow increase in early and late phase of the stimulation in control (n = 5) and Eng-iKOe(n = 8) mice. All error bars represent SEM. P value result from unpaired / -tests.

[0029] Figure 6: Impaired TGF-P bioavailability in Eng-iKCE mice, (a) Schematic showing adult induction of Eng deletion in endothelial cells. At day 9, retinas of Eng-iKOemice were harvested and incubated for three hours in medium containing TGF-pi (5 ng.mL'1) (n = 5, total EPs = 30) or vehicle alone (n = 5, total EPs = 26) in the absence or presence of Actinomycin D (1 pg.mL'1) (n = 4, total EPs = 21), SB431542 (10 pM) (n = 3, total EPs =15), or Y27632 (100 pM) (n = 4, total EPs = 22), that inhibits the transcription, ALK5 or ROCK, respectively. Pericytes were then subjected to electrical stimulation. Retinas of control mice (n = 4, total EPs = 18) were in medium alone, (b) Proportion of EPs inducing a vascular constriction at the indicated current (pA) and (c) mean intensity inducing EP-mediated vessel constriction in the different conditions, (d) TGF-P modulates pericyte vasocontraction / relaxation. TGF-P is produced in an inactive form by both endothelial cells and pericytes. Activation of TGF-P requires direct interactions between these two cell types. In Eng-iKOemice, pericytes establish only loose connections with the endothelium leading to a lack of active TGF-P availability. This causes a reduced ALK5-mediated RhoA / Rock activity within pericytes leading to their relaxation. All error bars represent SEM. P values result from 1-way ANOVA and Dunnett’s post hoc tests comparing the mean of each group to the control group.

[0030] Figure 7: C381 drug restores pericyte attachment velocity and tortuosity phenotype, (a) Diagram of the injection scheme, (b) Quantification of EP and MP roundness in control (n = 4, total EPs = 24, MPs = 37), Eng-iKOe(n = 4, total EPs = 23, MPs = 57) and Eng-iKOemice treated with C381 (n = 3, total EPs = 29, MPs = 46). (c and d) Mean intensity inducing EP (c) and MP-mediated contraction (d) in control (n = 5, total EPs = 49, MPs = 41) and Eng-iKOe(n = 8, total EPs = 46, MPs = 46) and Eng-iKOemice treated with C381 (n = 5, total EPs = 24, MPs = 21) mice, (e) Quantification of MB velocity in arterioles in control (n = 12, total vessels = 200), Eng-iKOe(n = 13, total vessels = 249), Eng-iKOemice treated with C381 (n = 6, total vessels = 202) and Eng-iKOemice treated with VAD044 (n = 3, total vessels = 45). (f) Quantification of arteriolar tortuosity in control (n = 10, total vessels = 77), Eng-iKOe(n = 11, total vessels = 77), Eng-iKOemice treated with C381 (n = 5, total vessels = 41) and Eng-iKOe mice treated with VAD044 (n = 3, total vessels = 23). All error bars represent SEM. P valuesresult from 1-way ANOVA and Dunnett’s post hoc tests comparing the mean of each group to the control group.

[0031] Figure 8: C381 drug restore haemodynamic response, (a) Quantification of the baseline CBV, (b) average of the haemodynamic response within a chosen region of interest, (c) quantification of the increased response amplitude (d) quantification of the rise time was performed in control (n = 15), Eng-iKOe(n = 11) and Eng-iKOemice treated with C381 (n = 10). (e) Mean timeseries of MB flow increase, (f) Quantification of the MB flow increase in control (n = 11), Eng-iKOe(n = 11) and Eng-iKOemice treated with C381 (n = 11). (g) Mechanisms of action by which VAD044 and C381 restore blood vessel dysfunction, as revealed by fULM. All error bars represent SEM. P values result from 1-way ANOVA and Dunnett’s post hoc tests comparing the mean of each group to the control group.

[0032] Figure 9: Mural cell function in the retina and physiological state of the brain in adult RVCL-S mice. (A) Top, a vascular segment of a retina with a contractile pericyte before (T=0s), during (T=6s), and after (T=40s) electrical stimulation. Scale bar, 20 pm. Bottom, mean current ( A) inducing vSMC (left) and EP (right) mediated contraction in 7 / vx""!'and control mice. (B) Top, confocal images of immunohistochemical stainings of brain sections, specifically the region of the somatosensory cortex, showing high magnification representative image of a capillary (Glut 1 -positive endothelial cells) that are covered by pericytes (CD13-postove pericytes), quantified in Trexmutand control mice at the bottom. (C) Brain section of a Trexmutmouse showing Fluor-555 cadaverine. (D) Top, confocal images of immunohistochemical stainings of the brain, specifically the region of the somatosensory cortex, showing microglia cells and lysosomes (Ibal and CD68) and quantification of Ibal and CD68 positive area. (E) Average of the hemodynamic response amplitude in 7 / vx""!'and control mice.

[0033] Figure 10: Analysis of the arteriolar architecture. (A) Normalized MB count of ULM maps of the mouse brain vasculature in both Trexmutand control mice. (B) blood flow velocity of ULM maps in both Trexmutand control mice and (C) quantification of velcity along arterioles (depth 0-400 pm of the cortex) during the resting period in both Trexmutand control mice. . DETAILED DESCRIPTION

[0034] Non-invasive method for detecting or monitoring mural cell dysfunction

[0035] In the present application, the inventors have shown that hemodynamic and / or vascular phenotype change in the arteriole zone and ACT zone, preferably in the brain can be used asbiomarkers to detect or monitor early mural cell dysfunction, preferably associated with neurological diseases before the onset of clinical symptoms. The early detection of mural cell dysfunction will enable to tailor therapeutic interventions. Moreover, continuous monitoring of mural cell function would not only improve the understanding of disease progression but also facilitate the evaluation of emerging therapeutic agents targeting the cellular mechanisms of mural cell dysfunction.

[0036] The term “biomarker” refers to a distinctive biological or biologically derived indicator (i.e., cellular, biochemical, molecular, genetic, protein, metabolite, specific post-translational modification or physiological or physical sign) of a process, event or condition. According to the present disclosure said biomarker may refer to a vascular or hemodynamic phenotype change. A vascular or hemodynamic phenotype is a single or combined group of vascular or hemodynamic parameter values that occur as a result of an altered or unaltered biological process or pathogenic medical condition, in particular mural cell dysfunction.

[0037] The present disclosure relates to a non-invasive method for detecting or monitoring an early mural cell dysfunction, preferably associated with a neurological disease in a human subject said method comprising determining or computing at least one hemodynamic and / or at least one vascular phenotype change compared to control value(s), in particular in a region of interest in the arteriole zone and / or Arteriolar-Capillary transition (ACT) zone, preferably in the brain of said human subject.

[0038] Mural cell dysfunction refers to abnormalities in the microvascular vessels, preferably of the brain that can lead to neurological diseases. Blood vessels are composed of endothelial cells that form the inner lining of the vessel walls and of mural cells referred to as vascular smooth muscle cells and pericytes. Vascular smooth muscle cells surround arteries and veins whereas pericytes enwrap intermediate to small-size capillaries. Early structural and functional changes of the microvasculature are often discrete and include mural cell death or migration away from the endothelium, increased blood capillary dilatation and tortuosity and variations in vessel density. These pathological responses can lead to long-lasting hypoperfusion, loss of blood brain barrier function and increase of immune cell entry to the brain, which together contribute to neuronal damage (Armulik, A. et al. Nature 468, 557-561 (2010), Berthiaume, A. A. et al. Nat Commun 13, 5912 (2022).

[0039] According to the present disclosure, mural cell induced microvascular blood vessel abnormalities are detected or monitored in the arteriole zone and / or ACT zone.An arteriole is a small-diameter blood vessel (i.e., with an average of around 10 gm), in the microcirculation that extends and branches out from an artery and leads to capillaries.

[0040] Arteriolar-Capillary Transition (ACT) zone, also named post-arteriole transitional zone, refers to the segment of the microvascular network where arterioles transition into capillaries. The ACT has a baseline lumen diameter range from 2 to 10 gm, with an average of around 5 gm. This zone can be characterized by a drop of a-SMA expression. The ACT zone occurs generally anywhere between the first and fourth branch orders and comprises ensheathing pericytes (EP) that are first to respond during the regional blood flow increase during neurovascular coupling (Hartmann D. A. et al. Annu. Rev. Physiol. 2022. 84:331-54). This zone plays a critical role in regulating blood flow and pressure as it moves from larger vessels to the smaller capillary beds. Damage to the arteriole and transitional zone causes cerebral hypoperfusion, ischemia, or hypoxia, all of which lead to oxidative stress and induce microvascular inflammation. Microvascular impairment can also increase the infiltration of peripheral immune cells into the central nervous system (CNS), which then cooperate with CNS resident immune cells to induces neuroinflammation. Damage to the arteriole and transitional zone can also compromise the Blood Brain Barrier (BBB), allowing harmful substances to enter the brain and potentially leading to neuroinflammation or neurodegenerative diseases.

[0041] According to the present disclosure, said hemodynamic phenotype change may be determined or computed by comparing at least one, preferably two or three hemodynamic parameter value(s) selected among: blood flow, blood volume, blood pressure and blood velocity, previously measured in a region of interest in the arteriole zone or ACT zone, preferably in the brain, with corresponding control value(s).

[0042] According to the present disclosure, said vascular phenotype change may be determined or computed by comparing at least one, preferably two vascular parameter value(s) selected among vessel diameter, vessel length, and vessel tortuosity, previously measured in a region of interest of the arteriole zone or ACT zones, preferably in the brain, with corresponding control value(s).

[0043] In a particular embodiment, the method according to the present disclosure comprises comparing at least one vascular parameter value selected among vessel diameter and vessel tortuosity and / or at least one hemodynamic parameter value selected among: blood velocity, blood flow, blood pressure and blood volume, previously measured in a region of interest of the arteriole zone or ACT zones, preferably in the brain, with corresponding control value(s).In a preferred embodiment, the present disclosure comprises comparing vessel diameter and blood velocity; vessel diameter and blood flow; vessel diameter and blood pressure; vessel diameter and blood volume; vessel tortuosity and blood velocity; vessel tortuosity and blood pressure; vessel tortuosity and blood flow; or vessel tortuosity and blood volume parameter values, previously measured in a region of interest of the arteriole zone or ACT zone, preferably in the brain, with corresponding control value(s), preferably comparing vessel diameter, vessel tortuosity and blood velocity; vessel diameter, vessel tortuosity and blood flow; vessel diameter, vessel tortuosity and blood pressure; or vessel diameter, vessel tortuosity and blood volume parameter values, previously measured in a region of interest of the arteriole zone or ACT zone, preferably in the brain, with corresponding control values; more preferably vessel diameter, vessel tortuosity and blood velocity parameter values previously measured in a region of interest of the arteriole zone or ACT zone, preferably in the brain, with corresponding control values.

[0044] The vascular or hemodynamic parameter value may be determined by any suitable methods known by the person skilled in the art in a patient sample. In a preferred embodiment, said hemodynamic and / or vascular parameter values are previously measured with Ultrasound imaging such as Ultrasound Localization Microscopy (ULM) and / or functional Ultrasound imaging (fUS), preferably ULM and fUS.

[0045] By Ultrasound Localization Microscopy (ULM), it is meant both the imaging of the vascular structure and its function. The structure is described by many parameters (such as vessel density, vessel length, vessel tortuosity, vessel diameter,...). The function of the vascular system can be assessed by quantifying baseline hemodynamic parameters at rest (such as blood flow, blood velocity, blood acceleration, blood turbulence,...) but also their variations during cardiac pulsatility, task-evoked stimuli, spontaneous activity, the effect of a drug, the effect of an exercise.

[0046] In a particular embodiment, hemodynamic and / or vascular parameter value can be measured according to a method of conventional Ultrasound Localization Microscopy imaging, already known in the art, preferably as described in WO2023 / 156576 or Renaudin N. et al. Nature Methods volume 19, pages 1004-1012 (2022), or in Example 1.8 of the present application. In particular, said hemodynamic and / or vascular parameter values are measured by a) performing a temporal series of Ultrasound Localization Microscopy (ULM) images in the arteriole zone or Arteriolar-Capillary transition (ACT) zone, to obtain values of at least one vascular orhemodynamic parameter in at least one area of interest in the arteriole zone or Arteriolar-Capillary transition (ACT) zone during a recording period, the temporal series of ULM images being constructed from a temporal series of images of the region, each ULM image being constructed from a stack of images of the temporal series of images, at least some of the images of a stack of images corresponding to a (k+l)th ULM image having a time position superior to that of the images of a stack of images corresponding to a kth ULM image which is immediately preceding the (k+l)th ULM image, said recording period of the temporal series of ULM images including at least one dynamical event, due to a cause other than cardiac pulsatility, the dynamical event activating a change in an hemodynamic and / or a change in a structural conformation of the vascular network in the at least one region thereof; (b) computing, based on the values of the at least one vascular or hemodynamic parameter from the temporal series of ULM images, a measure of an evolution of the at least one vascular or hemodynamic parameter in response to the dynamical event. In a preferred embodiment, said ultrasound measurements are based on ultrafast ultrasound imaging with a Pulse Repetition Frequency over 500 Hz.

[0047] In a more particular embodiment, in order to obtain a 3D rendering perception in the vascular map, said hemodynamic and / or vascular parameter values can be measured according to a method of Ultrasound Localization Microscopy imagin, preferably with speed, density or backscattering Ultrasound Localization Microscopy (ULM) as described in WO2024218060 or Renaudin N. et al. Scientific Reports volume 13, Article number: 11477 (2023). Ultrasound Localization Microscopy (ULM) relies on several key parameters to achieve super-resolution imaging, including speed, density, and backscattering. In ULM, speed refers to the velocity of microbubbles as they travel through the bloodstream. By tracking their movement at high frame rates, one can generate detailed maps of blood flow in microvascular networks. The density of microbubbles in the bloodstream affects the quality of ULM images. A higher density can improve visualization but may also introduce noise, making it harder to distinguish individual microbubbles. Microbubble concentration can be optimized to balance resolution and sensitivity. Backscattering refers to the reflection of ultrasound waves from microbubbles. Recent studies have shown that analyzing backscattering amplitude can enhance sensitivity in ULM, allowing for better visualization of microvascular structures, in particular by (a) transmitting a series of successive incident ultrasonic waves in the at least one area by an array of ultrasonic transducers, the array of ultrasonic transducers extending along at least one direction and the incident ultrasonic waves being propagated in a direction perpendicular to thearray of transducers; (b) acquiring a set of raw data from backscattered ultrasonic waves by said array of transducers; (c) generating a series of successive ultrasound images from said raw data; (d) detecting at least one isolated ultrasound contrast agent in the ultrasound images; (e) localizing the position of said at least one isolated ultrasound contrast agent with a precision inferior to the wavelength of the waves; (f) generating at least one 2D backscattering amplitude image by attributing for each pixel a value representative of the measured backscattering amplitude of at least one isolated ultrasound contrast agent detected in said pixel. In a preferred embodiment, said ultrasound measurements are based on ultrafast ultrasound imaging with a Pulse Repetition Frequency over 500 Hz.

[0048] In another particular embodiment, hemodynamic and / or vascular parameter value can be measured according to a method of functional ultrasound (fUS) imaging, already known in the art, preferably as described in W02012 / 080614 or Mace et al. et al. Nature Methods 2011 Jul 3;8(8):662-4, or in Example 1.8 of the present application. By functional Ultrasound (fUS), it is meant medical ultrasound imaging technique for detecting or measuring changes in activities or metabolism, such as brain activity loci, typically through measuring hemodynamic (blood flow) changes. It is an extension of Doppler ultrasonography. fUS uses plane-wave illumination at high frame rate and can measure blood volume in smaller vessels and can allow to image transient changes in blood volume in the whole brain.

[0049] In a particular embodiment, a contrast agent is previously administered to said subject before measuring the vascular and / or hemodynamic parameter values, preferably before acquiring the images. The ultrasound contrast agent injection may be a bolus injection, preferably with a maximum injection volume of 10 mL. For instance, two bolus of 2.4 mL may be injected in the human.

[0050] The ultrasound contrast agent injection may be a continuous injection. For instance, a flow rate of the continuous injection may be comprised between 3 mL / h / kg and 60 mL / h / kg, and preferably approximatively 10 mL / h / kg (or typically 3.5 mL / h for a 300 g rat and 1.0 mL / h for a 70 g mice). Continuous injections enable a stable number of microbubbles for more than 20 minutes with approximately 30 microbubbles per ultrasound frame which correspond to a compound image.

[0051] In one or more embodiments, the computation of the measure of the evolution of the at least one vascular or hemodynamic parameter may comprise a more sophisticated processinganalysis, comprising but not restricted to, Singular Value Decomposition (SVD) or a Principal Component Analysis (PCA), of the temporal series of ULM images.

[0052] In a particular embodiment, the vessel diameter may be obtained by different segmentation techniques applied to the ULM images. In its simplest form, it could be defined as a width of the vessel at a threshold set by the Half Maximum of a rest profile. Blood flow may be derived from a ULM contrast agents’ flow during a recording of the temporal series. Blood velocity may be derived from a ULM contrast agents’ velocity during a recording of the temporal series. In another particular embodiment, the method can also comprise a step of determining the neurovascular coupling in a region of the arteriole zone or ACT zone, in particular by delivering a nervous stimulus and determining or computing the vascular and / or hemodynamic phenotype change as described above in response to said nervous stimulus. Said nervous stimulus can be sensorial, in particular optical, auditive, odour, taste, contact, shock or electrical stimulus. The vascular or hemodynamic parameter value may be determined by any suitable methods known by the person skilled in the art in a patient sample. The vascular and / or hemodynamic phenotype response to said nervous stimulus can correspond to a peak value of the vascular and / or hemodynamic phenotype, a rise time computed from the stimulus to the time of the peak value of the vascular and / or hemodynamic response, a fall time computed from the time of the peak value of the vascular and / or hemodynamic response to a minimum value of the response following said peak value. In a preferred embodiment, said hemodynamic and / or vascular phenotype change are measured with Ultrasound Localization Microscopy (ULM), more preferably as described in W02023 / 062075.

[0053] To determine or compute an hemodynamic or vascular phenotype change; or hemodynamic or vascular phenotype change in response to a stimulus, preferably a nervous stimulus in a human subject according to the present method, the hemodynamic and / or vascular parameter values or hemodynamic or vascular response to the stimulus previously measured in a region of interest of the arteriole zone or ACT zone, preferably in the human subject brain is compared to corresponding control value(s).

[0054] According to the present disclosure, the terms “threshold value”, “control value” or “cut-off value” can be used interchangeably and can be determined experimentally, empirically, or theoretically. The control value may refer to hemodynamic and / or vascular parameter value(s) or hemodynamic and / or vascular response to a stimulus, preferably a nervous stimulus (e.g.,peak value, rise time, fall time) in a region of interest of arteriole zone or ACT zone in general population or from a selected population of subjects. For example, the general population may comprise apparently healthy subjects, such as individuals who have not been diagnosed as having a mural cell dysfunction or mural cell dysfunction associated to neurological disease, and / or previously had any sign or symptoms indicating the presence of mural cell dysfunction. The term "healthy subjects" as used herein refers to a population of subjects who do not suffer from any known condition, and in particular, who do not present any cerebrovascular dysfunction.

[0055] The control value may be established based upon comparative measurements between human subject having mural cell dysfunction and healthy human subject and calculating the statistical significance between the hemodynamic and / or vascular parameter value or hemodynamic and / or vascular response to a stimulus (e.g., peak value, rise time, fall time) of a collection of patient samples and the healthy subjects. Said predetermined control value (cut-off value) can consists of the value for which the highest statistical significance is calculated. Typically, the control value can be determined using a Receiver Operating Characteristic (ROC) curve based on experimental data. For example, after determining the vascular and / or hemodynamic parameter value or hemodynamic and / or vascular response to a stimulus (e.g., peak value, rise time, fall time) in a group of reference, one can use algorithmic analysis for the statistic treatment of the measured values in subject to be tested, and thus obtain a classification standard having significance for sample classification. In a particular embodiment, Receiver operating characteristic (ROC) analysis was performed to calculate the vascular and / or hemodynamic parameter value using patient samples with known clinical status. The vascular and / or hemodynamic parameter value offering the highest sensitivity and specificity was selected as cut-off point. This algorithmic method is preferably done with a computer. Existing software or systems in the art may be used for the drawing of the ROC curve, such as: MedCalc 9.2.0.1 medical statistical software, SPSS 9.0, ROCPOWER.SAS, DESIGNROC.FOR, MULTIREADER POWER.SAS, CREATE-ROC.SAS, GB STAT VIO.O (Dynamic Microsystems, Inc. Silver Spring, Md., USA), etc.

[0056] In a particular embodiment, the method according to the present disclosure makes it possible to monitor mural cell dysfunction as described above in a human subject, and determine or compute hemodynamic or vascular phenotype change or hemodynamic or vascular phenotype change in response to a stimulus, preferably nervous stimulus over time, preferably in the same region of interest in the arteriole zone or ACT zone in the human subject brain. In this particularembodiment, the control value(s) may be the hemodynamic and / or vascular parameter value(s) measured in the same human subject at a previous time, preferably in the same region of interest in the arteriole zone or ACT zone, preferably in the brain.

[0057] In a particular embodiment, the human subject may be a subject already diagnosed with an inherited neurological disease, and the method makes it possible to detect and monitor over time mural cell dysfunction before the onset of neurological symptoms and to adjust the treatment accordingly.

[0058] According to the present disclosure, each hemodynamic and / or vascular parameter value or vascular phenotype change in response to a stimulus over time is determined in a region of interest in the arteriole zone or ACT zone, preferably in the brain and each value is compared to a corresponding control value. A change in a vascular and / or hemodynamic phenotype or vascular phenotype change in response to a stimulus over time compared to a control value is indicative that said subject is likely to have a mural cell dysfunction and appropriate treatment may be administered accordingly. No change in a vascular and / or hemodynamic phenotype or vascular phenotype change in response to a stimulus over time compared to a control value is indicative that said subject is unlikely to have mural cell dysfunction.

[0059] Mural cell dysfunction is associated with abnormalities in the microvascular blood vessels that can lead to neurological diseases. There are at least four types of mural cells, which define four major microvascular zones: Smooth Muscle Cells (SMCs) on pial and penetrating arterioles, ensheathing pericytes on the arteriole-capillary transition (ACT), capillary pericytes (displaying mesh and thin-strand processes) on capillaries, and venular SMCs on ascending and pial venules. Mural cells are involved in maintaining blood-brain barrier, regulating blood flow, influencing immune cell entry and be crucial for angiogenesis. Mural cell dysfunction can induce BBB breakdown that precedes neurodegeneration, can induce neuron death, and impaired neurovascular coupling.

[0060] In a particular embodiment, said mural cell dysfunction can include vascular smooth muscle cell dysfunction or pericyte dysfunction. In a particular embodiment, said mural cell dysfunction can be associated with hereditary disease, preferably selected from the group consisting of: Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), Cerebral Autosomal Recessive Arteriopathy with Subcortical infarcts and Leukoencephalopathy (CARASIL), HTRA1 -autosomal dominant disease, Col4-related autosomal disease such as Collagen 4A1 and collagen 4A2microangiopathy, Cathepsin-A-related arteriopathy with strokes and leukoencephalopathy (CARASAL), Retinal Vasculopathy with Cerebral Leukoencephalopathy and systemic manifestations (RVCL-S), Hereditary Hemorrhagic Telangiectasia (HHT), Fabry’s disease, Mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS), Cerebral Amyloid Angiopathy (CAA), Homocystinuria recessive disease, Sickle Cell disease, Parkes Weber syndrome, and CM-AVM syndrome, preferably Hereditary Hemorrhagic Telangiectasia (HHT).

[0061] In another particular embodiment, said mural cell dysfunction can be associated with non-genetic disease, preferably selected from the group consisting of: stroke, traumatic brain injury, migraine, epilepsy, spinal cord injury, diabetes, Huntington’s disease, Alzheimer’s disease, Parkinson’s disease, Radiation necrosis, Amyotrophic lateral sclerosis, Vascular dementia, and Wybur-Mason syndrome.

[0062] In a more particular embodiment, the mural cell dysfunction can be for example associated with a neurological disease selected from the group consisting of: stroke, in particular blood flow impairment in the acute stages of stroke, Alzheimer’s disease, vascular dementia, migraine, epilepsy, Huntington’s disease, Parkinson disease, Hereditary Haemorrhagic Telangiectasia (HHT) and Retinal Vasculopathy with Cerebral Leukoencephalopathy (RCVL), preferably Hereditary Haemorrhagic Telangiectasia (HHT).

[0063] According to the present disclosure, mural cell dysfunction can be detected or monitored in a human subject by determining at least one vascular and / or at least one hemodynamic phenotype change, preferably at least one vascular phenotype change and at least one hemodynamic phenotype change compared to corresponding control value(s) in a region of interest in the arteriole zone or ACT zone, preferably in the brain in a human subject.

[0064] In particular, said vascular phenotype change is determined or computed by comparing at least one vascular parameter value selected among: vessel diameter, vessel length and vessel tortuosity with corresponding control value(s) in a region of interest in the arteriole zone or ACT zone, preferably in the brain in a human subject and said hemodynamic phenotype change is determined by comparing at least one hemodynamic parameter value selected among blood volume, blood flow, blood pressure and blood velocity with corresponding control value(s) in a region of interest in the arteriole zone or ACT zone, preferably in the brain in a human subject.In a preferred embodiment a higher vessel diameter, higher vessel tortuosity, and / or lower blood velocity in a region of interest in the arteriole zone or ACT zone, preferably in the brain in a human subject is indicative that said subject presents mural cell dysfunction as described above. In a more preferred embodiment, a higher vessel diameter and higher vessel tortuosity; or higher vessel diameter and lower blood velocity; or higher vessel tortuosity and lower blood velocity in a region of interest in the arteriole zone or ACT zone, preferably in the brain in a human subject is indicative that said subject has a mural cell dysfunction, preferably associated with neurological disease as described above.

[0065] In another particular embodiment, the method can further comprise a step of determining the neurovascular coupling in a region of interest in the arteriole zone or ACT zone, in particular by delivering a stimulus, preferably a nervous stimulus and comparing the vascular and / or hemodynamic phenotype change as described above in response to said stimulus to corresponding control value(s).

[0066] In a preferred embodiment, a further lower change in blood volume in a region of interest in the arteriole zone or ACT zone in response to a stimulus, preferably a nervous stimulus, preferably early phase of said stimulus, compared to a control value is indicative that said subject has a mural cell dysfunction as described above.

[0067] A change in a hemodynamic and / or vascular phenotype and preferably a change in vascular and / or hemodynamic phenotype in response to a stimulus, preferably a nervous stimulus determined in a region of interest in the arteriole zone or ACT zone, preferably in the brain of the human subject compared to a corresponding control value(s) is indicative that said subject is likely to have a mural cell dysfunction as described above and appropriate treatment may be administered accordingly. No change in a vascular and / or hemodynamic phenotype compared to a control value is indicative that said subject is unlikely to have mural cell dysfunction. The methods as described above are preferably computer-implemented methods, for example implemented by computer executing code instructions stored on a memory.

[0068] In a particular embodiment, the present disclosure relates to the computer-implemented method as described above comprising the following steps:

[0069] i) incorporating in a software a set of parameters comprising the hemodynamic and / or vascular parameter values or hemodynamic or vascular response to thestimulus previously measured in a region of interest of the arteriole zone or ACT zone, preferably in the human subject brain, preferably wherein said vascular parameter value is selected among vessel diameter, vessel length and vessel tortuosity and hemodynamic parameter values is selected among: blood velocity, blood flow, blood pressure and blood volume;

[0070] ii) comparing said set of parameters to corresponding control value(s),

[0071] iii) concluding that said subject is likely to have mural cell dysfunction from said at least one vascular and said least one hemodynamic phenotype change compared to corresponding control value(s).

[0072] The non-invasive method for detecting or monitoring early mural cell dysfunction in a human subject according to the present disclosure also indicates which treatment should be administered to said human subject. Indeed, the treatment may be adjusted to specifically target a signaling pathway involved, for example in angiogenesis, neuroinflammation, mural cell function depending on the vascular or hemodynamic phenotype change determined in the arteriole zone or ACT zone, preferably in the brain of the human subject.

[0073] The present disclosure relates to a therapeutic agent for use in the treatment of a disease, preferably a neurological disease, associated with mural cell dysfunction in a human subject in need thereof wherein said therapeutic agent is administered in a patient previously identified as having a mural cell dysfunction using the method described above.

[0074] The present disclosure relates to a method for treating a disease associated with mural cell dysfunction, preferably a neurological disease associated with a mural cell dysfunction as described above in a human subject in need thereof comprising:

[0075] i) determining at least one vascular and / or at least one hemodynamic phenotype change in a region of interest in the arteriole zone or arteriole-capillary transition (ACT) zone, preferably in the brain in said human subject compared to corresponding control value(s), wherein said vascular phenotype change is determined by comparing at least one vascular parameter value selected among vessel diameter, vessel length and vessel tortuosity with corresponding control value(s) and said hemodynamic phenotype change is determined by comparing at least one hemodynamic parameter value selected among:blood velocity, blood flow, blood pressure and blood volume with corresponding control value(s),

[0076] ii) administering a therapeutically effective amount of said therapeutic agent to said patient previously identified as having a mural cell dysfunction.

[0077] The present disclosure relates to a computer-implemented method for treating a disease associated with mural cell dysfunction, preferably a neurological disease associated with a mural cell dysfunction as described above in a human subject in need thereof comprising: i) incorporating in a software a set of parameters comprising the hemodynamic and / or vascular parameter values or hemodynamic or vascular response to the stimulus previously measured in a region of interest of the arteriole zone or ACT zone, preferably in the human subject brain, preferably wherein said vascular parameter value is selected among vessel diameter, vessel length and vessel tortuosity and hemodynamic parameter values is selected among: blood velocity, blood flow, blood pressure and blood volume;

[0078] ii) comparing said set of parameters to corresponding control value(s),

[0079] iii) concluding that said subject is likely to have mural cell dysfunction from said at least one vascular and said least one hemodynamic phenotype change compared to corresponding control value(s).

[0080] iv) administering a therapeutically effective amount of said therapeutic agent to said patient previously identified as likely to have a mural cell dysfunction.

[0081] In the context of the present disclosure, the term "treating" or "treatment", as used herein, means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or reversing, alleviating, inhibiting the progress of, or preventing one or more symptoms of the disorder or condition to which such term applies.

[0082] Such treatment aims at improving the clinical status of the human patient, by eliminating or lowering the symptoms associated with pericyte dysfunction.

[0083] As used herein, a "therapeutically effective amount" or an "effective amount" means the amount of a composition that, when administered to a subject for treating a state, disorder or condition is sufficient to effect a treatment. The therapeutically effective amount will vary depending on the composition, the disease and its severity and the age, weight, physical condition and responsiveness of the subject to be treated.The present disclosure also relates to the use of therapeutic agent in the manufacture of a medicament for the treatment of a disease associated with a mural cell dysfunction, preferably neurological disease associated with a mural cell dysfunction in a human subject in need thereof previously identified as having mural cell dysfunction in the method as described above.

[0084] According to the present disclosure, therapeutic agents that can be used to treat a disease, preferably a neurological disease associated with mural cell dysfunction are as non-limiting examples: anti-angiogenic drug, anti-inflammatory drug, mural cell targeting drug or Immunomodulatory imide drugs (IMiDs), and Rho signaling inhinbitor.

[0085] Anti-angiogenic drug can be selected from the group consisting of: Vascular endothelial growth factor (VEGF) inhibitor such as Avastin (bevacizumab), Eylea (aflibercept), Lucentis (ranibizumab), Nexavar (sorafenib), Sprycel (dasatinib), Sutent (sunitinib), Tasigna (nilotinib), or Votrient (pazopanib); Angiopoietin inhibitor such as Trebananib, angioipoietin antibodies, Tyrosine kinase inhibitor such as imatinib, gefitinib, sorafenib, pazopanib, erlotinib, dasatinib, sunitinib, adavosertib or lapatinib; Phosphoinositide 3-kinase (PI3K) inhibitor such as Idelalisib, Duvelisib, Alpelisib, Umbralisib, Leniolisib, Dactolisib, Parsaclisib, Paxalisib, Taselib, Zandelisib, Inavolisib, Buparlisib, CH5132799, Piralisib, ZSTK474, Sonolisib, Pictilisib, Copanlisib, B591, TG-100-115, or RIDR-PI-103, Akt inhibitor such as MK-2203, Capivasertib, GSK690693, Ipatasertib, or Tricirbine, mTor inhibitor such as temsirolimus, temsirolimus (CCI-779), everolimus (RAD001), ridaforolimus (AP-23573), Rapalogs, sirolimus, umirolimus, or zotarolimus; Meiotic Checkpoint Kinase inhibitor (MEK1 / 2 inhibitor) such as Trametinib, Cobimetinib, Binimetinib, Selumetinib, Mirdametinib, or PD-0325901.

[0086] Anti-inflammatory drug can be selected from the group consisting of: Non-steroidal antiinflammatory drugs (NS AID), Mitogen- Activated protein kinase (MAPK) inhibitor such as RWJ-67657 (p38 inhibitor), BIRB 76 (p38 inhibitor), VX-745 (p38 inhibitor), VX-702 (p38 inhibitor), SCIO-469, SP600125 (JNK inhibitor), CC-401 (JNK inhibitor), CEP-1347 (JNK inhibitor), AS600292 (JNK inhibitor) or PD0325901 (ERK inhibitor); Tumor necrosis factor (TNF) inhibitor such as infliximab, adalimumab, certolizumab, certolizumab pegol, golimumab, etarnercept, pentoxifylline, burpropion, thalidomide, lenalidomide or pomalidomide.

[0087] Mural cell targeting drug can be selected from the group consisting of: Transforming Growth Factor (TGF) P agonist such as SRI-011381 (C381), Isoxazole 9 (ISX-9), or activin A, Platelet derived Growth Factor (PDGF) inhibitor such as suramin sodium, 4-chloro-6,7-(2-methoxy-ethoxy)-quinazoline, sennoside B, Nilvadipine, 4-Dechloro-2-chloro-regorafenib, Imatinib, Sorafenib, sunitinib, or CP-673451.

[0088] Immunomodulatory imide drugs (IMiDs) are a class of immunomodulatory drugs containing imide group. IMiDs are structural and functional analogs of thalidomide, a glutamic acid derivative with anti-angiogenic properties and potent anti-inflammatory effects owing to its anti-tumour necrosis factor (TNF)a activity. IMiDs can include as non-limiting examples, thalidomide, Lenalidomide, pomalidomide, Mezigdomide and Iberdomide.

[0089] Rho signalling inhibitors are compounds that target the Rho-associated protein kinase (ROCK) pathway, which plays a crucial role in cell contraction, motility, proliferation, and apoptosis. By inhibiting this pathway, these drugs can regulate cytoskeletal dynamics, making them valuable in treating conditions like cardiovascular diseases, glaucoma, and cancer. Rho signaling inhibitors can include as non-limiting examples: cyclohexanecarboxamides such as Y-27632 ((+)-(R)-trans-4-(l-aminoethyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride) and Y-30131 ((+)-(R)-trans-4-(l-aminoethyl)-N-(lH-pyrrolo[2, 3-b]pyridin-4-yl)cyclohexanecarboxamide dihydrochloride), as well as Y-30141, Y-33075, and Y-39983; dihydropyrimidinones and dihydropyrimidines, e.g., bicyclic dihydropyrimidine-carboxamides (such as those described in Sehon et al. J. Med. Chem., 2008, 51 (21): 6631-6634 and US2018 / 0170939); ureidobenzamides such as CAY10622 (3-[[[[[4-(aminocarbonyl) phenyl]amino]carbonyl]amino]methyl]-N-(l, 2, 3, 4-tetrahydro-7-isoquinolinyl)-benzamide); Thiazovivin; GSK429286A; RKI-1447 (l-(3-Hydroxybenzyl)-3-(4-(pyridin-4-yl)thiazol-2-yl)urea); GSK180736A (GSK180736); Hydroxyfasudil (HA-1100); OXA 06; Y-39983; Netarsudil (AR-13324, see Lin et al., J Ocul Pharmacol Then 2018 Mar. 1; 34(1-2): 40-51, U.S. Pat. Nos. 8,450,344 and 8,394,826); GSK269962 / GSK269962A; Fasudil (HA-1077, l-(5-isoquinolinesulfonyl)-homopiperazine) and its derivatives such Ripasudil (K-115, 4-fluoro-5-[[(2S)-2-methyl-l,4-diazepan-l-yl]sulfonyl]isoquinoline; see WO 1999 / 20620) and others that share the core structure of 5-(l,4-diazepan-l-ylsulfonyl)isoquinoline; KD025 (SLx-2119) and related compound and XD-4000 (see, e.g. Liao et al. 2007 J Cardiovasc Pharmacol 50:17-24; W02010 / 104851 US 2012 / 0202793); SR 3677; AS 1892802; H-1152 ((S)-(+)-2-Methyl-l-[(4-methyl-5-isoquinolinyl)sulfonyl] homopiperazine, Ikenoya et al., J. Neurochem. 81:9, 2002; Sasaki et al., Pharmacol. Then 93:225, 2002); N-(4-Pyridyl)-N'-(2,4,6-trichlorophenyl)urea (Takami et al., Bioorg. Med. Chem. 12:2115, 2004); and 3-(4-Pyridyl)-lH-indole (Yarrow et al., Chem. Biol. 12:385, 2005); 3-[2-(aminomethyl)-5-[(pyridin-4-yl)carbamoyl]phenyl] benzoates including AMA0076 (compound 32, Boland et al., Bioorganic & MedicinalChemistry Letters 23(23): 6442-6446 (2013)); TCS-7001, BA-210, P-Elemene, Chroman 1, (5Z)-2-5-(lH-pyrrolo[2,3-b]pyridine-3-ylmethylene)-l,3-thiazol-4(5H)-one (DJ4), GSK-576371, GSK429286A, LX-7101, Verosudil (AR-12286), or AT13148.

[0090] The present disclosure also relates to a pharmaceutical composition comprising a therapeutic agent as described above for use in the treatment of a disease, preferably a neurological disease associated with mural cell dysfunction in a human subject in need thereof, preferably wherein said pharmaceutical composition is administered in a human subject previously identified as having mural cell dysfunction using the methods as described previously.

[0091] Said pharmaceutical composition may comprise a therapeutic agent selected from the group consisting of: anti-angiogenic agent; anti-inflammatory agent, mural cell targeting drug, IMiDs, and Rho signaling inhinbitor, as described above.

[0092] Said pharmaceutical composition can comprise one or more pharmaceutical acceptable excipient, diluent or carrier. As used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency or recognized pharmacopeia such as European Pharmacopeia, for use in animals and / or humans. The term "excipient" refers to a diluent, adjuvant, carrier, or vehicle with which the therapeutic agent is administered.

[0093] Any suitable pharmaceutically acceptable carrier, diluent or excipient can be used in the preparation of a pharmaceutical composition (See e.g., Remington: The Science and Practice of Pharmacy, Alfonso R. Gennaro (Editor) Mack Publishing Company, April 1997). Pharmaceutical compositions are typically sterile and stable under the conditions of manufacture and storage. Pharmaceutical compositions may be formulated as solutions (e.g. saline, dextrose solution, or buffered solution, or other pharmaceutically acceptable sterile fluids), microemulsions, liposomes, or other ordered structure suitable to accommodate a high product concentration (e.g. microparticles or nanoparticles). The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition.The composition may be administered by any means known to those skilled in the art, including, without limitation, intravenously, orally, intra-tumoral, intra-lesional, intradermal, topical, intraperitoneal, intramuscular, parenteral, subcutaneous and topical administration. Thus, the composition may be formulated as an injectable, topical, or ingestible formulation. Administration of the composition to a subject in accordance with the present disclosure may exhibit beneficial effects in a dose-dependent manner. Thus, within broad limits, administration of larger quantities of the composition is expected to achieve increased beneficial biological effects than administration of a smaller amount. Moreover, efficacy is also contemplated at dosages below the level at which toxicity is seen.

[0094] It will be appreciated that the specific dosage of an administered in any given case will be adjusted in accordance with the composition being administered, the volume of the composition that can be effectively delivered to the site of administration, the disease to be treated or inhibited, the condition of the subject, and other relevant medical factors that may modify the activity of the compositions or the response of the subject, as is well known by those skilled in the art.

[0095] For example, the specific dose of composition for a particular subject depends on age, body weight, general state of health, diet, the timing and mode of administration, the rate of excretion, medicaments used in combination and the severity of the particular disorder to which the therapy is applied. Dosages for a given patient can be determined using conventional considerations, e.g., by customary comparison of the differential activities of the immunotherapy and pharmaceutical compositions described herein and of a known agent, such as by means of an appropriate conventional pharmacological protocol. The composition can be given in a single dose schedule, or in a multiple dose schedule.

[0096] Method for evaluating the response to a therapeutic agent

[0097] In the present application, the inventors also demonstrated that the detection of a vascular and / or hemodynamic phenotype change in response to the medical treatment allow to efficiently monitor the impact of the medical treatment and evaluate the therapeutic response. The medical treatment may be adapted depending on vascular and / or hemodynamic phenotype change in response to the initial medical treatment.

[0098] The method disclosed in the present application allows to monitor accurately the therapeutic effect of compound in a human subject and adapt treatment, for example by specificallytargeting the signalling pathway regulating specific subpopulations and / or specific phase of the neurological disease.

[0099] The present disclosure relates to a non-invasive method for evaluating the response to a therapeutic agent as described above in a human subject suffering from a disease, preferably a neurological disease associated with a mural cell dysfunction as described above, comprising determining or computing at least one vascular phenotype and / or at least one hemodynamic phenotype change as described above compared to corresponding control value(s), in particular in a region of interest in the arteriole zone or ACT zone, preferably in the brain in said human subject.

[0100] “Therapeutic response” refers to the consequence of a medical treatment in a subject, the results of which are judged to be useful or favorable. For instance, a therapeutic response may be the delay or the prevention of at least one of the symptoms, upon or after treatment, or may be that the symptoms or at least one of the symptoms in patient stabilize, diminish or disappear.

[0101] The term “evaluating therapeutic response to treatment”, as used herein, refers to an ability to assess whether the treatment of a patient is likely effective in (e.g., providing a measurable benefit or positive medical response to) the patient after some time of administration of the treatment. In other terms, according to the present disclosure, evaluating the response to a treatment refers to an ability to assess the effect of therapeutic agent in patient, in particular on vascular and / or hemodynamic phenotype in arteriole zone or ACT zone which can be correlated with the likely responsiveness of said patient to said treatment.

[0102] The term "likely responder”, or “likely responsive to a treatment” refers to a subject in whom the onset of at least one of the symptoms of the condition to be treated is delayed or prevented, upon or after treatment, or whose symptoms or at least one of the symptoms stabilize, diminish or disappear.

[0103] The biomarkers according to the present disclosure make it possible to classify the patient as a responder or not of said treatment by determining at least one hemodynamic and / or at least one vascular phenotype change in a human patient compared to corresponding control value(s). In a particular embodiment, the determination of at least one hemodynamic and / or at least one vascular phenotype change as described above compared to corresponding control value(s), in the arteriole zone or ACT zone in a human subject is informative to the therapeutic effect of a compound in a patient and thus the efficacy of said treatment, during the course of the treatment.l ' l

[0104] In particular, the therapeutic effect of the compound in a patient and thus likely response to said therapeutic agent in a human patient is evaluated by comparing at least one hemodynamic and / or at least one vascular phenotype change compared to corresponding control value(s) in a subject having received at least one dose of said therapeutic agent.

[0105] The therapeutic response can be evaluated according to the present method, after each administration of a therapeutic agent throughout the course of treatment for monitoring the therapeutic response over time.

[0106] According to the present disclosure, said hemodynamic phenotype change may be determined or computed by comparing at least one, preferably two or three hemodynamic parameter value(s) selected among: blood flow, blood volume, blood pressure and blood velocity, previously measured in a region of interest in the arteriole zone or ACT zones, preferably in the brain, with corresponding control value(s).

[0107] According to the present disclosure, said vascular phenotype change may be determined or computed by comparing at least one, preferably two vascular parameter value(s) selected among vessel diameter, vessel length, and vessel tortuosity, previously measured in a region of interest in the arteriole zone or ACT zone, preferably in the brain, with corresponding control value(s).

[0108] In a particular embodiment, the method according to the present disclosure comprises comparing at least one vascular parameter value selected among vessel diameter and vessel tortuosity and at least one hemodynamic parameter value selected among: blood velocity, blood flow, blood pressure and blood volume, previously measured in a region of interest in the arteriole zone or ACT zone, preferably in the brain, with corresponding control value(s).

[0109] In another particular embodiment, the method can further comprise a step of determining or computing the neurovascular coupling in a region of the arteriole zone or ACT zone, preferably in the brain of said human subject, in particular by comparing a hemodynamic or vascular response change in response to a delivering a stimulus, preferably a nervous stimulus previously measured as described above with corresponding control value(s).

[0110] To determine or compute an hemodynamic or vascular phenotype change; or hemodynamic or vascular phenotype change in response to a stimulus, preferably a nervous stimulus in a human subject according to the present method, the hemodynamic and / or vascular parameter values or hemodynamic or vascular response to a stimulus previously measured in a region of interest ofthe arteriole zone or ACT zone in the human subject is compared to corresponding control value(s).

[0111] As used herein, the term "control value" may refer to the hemodynamic and / or the vascular phenotype change or hemodynamic or vascular phenotype change in response to a stimulus, preferably a nervous stimulus in a region of interest of the arteriole zone or ACT zone obtained from said patient at a different time, preferably in the same region of the arteriole zone or ACT zone, more preferably prior to said administration of therapeutic agent dose or prior to any treatment of the condition or disease. The control value may alternatively be a predetermined value such as a threshold value, a standard value or a range obtained from other source than the patient’s data. The control predetermined value may be established based upon comparative measurements between patients prior to said administration of therapeutic agent dose and patients having received said therapeutic agent dose administration.

[0112] A change in a hemodynamic and / or vascular phenotype and preferably a change in vascular and / or hemodynamic phenotype in response to a stimulus, preferably a nervous stimulus determined in a region of interest in the arteriole zone or ACT zone, preferably in the brain of the human subject compared to a corresponding control value(s) is indicative that said subject is likely responsive to said treatment, and the treatment may be re-administered accordingly. If after treatment with the therapeutic agent, no change in a vascular and / or hemodynamic phenotype compared to a control value is observed, the treatment should be interrupted or modified.

[0113] In another terms, a change in a hemodynamic and / or vascular phenotype and preferably a change in vascular and / or hemodynamic phenotype in response to a stimulus, preferably a nervous stimulus determined in a region of interest in the arteriole zone or ACT zone, preferably in the brain of the human subject compared to a corresponding control value(s), means an improvement in the hemodynamic and / or vascular phenotype which become close to the phenotypes observed in healthy subjects who do not present any mural cell dysfunctions. The human subject is likely responsive to the therapeutic agent if at least one vascular and / or hemodynamic phenotype is restored and approaches the phenotype observed in healthy subjects. Methods as described above can be computer-implemented methods, for example implemented by computer executing code instructions stored on a memory.In a particular embodiment, the present disclosure relates to the computer-implemented method as described above comprising the following steps:

[0114] i) incorporating in a software a set of parameters comprising the hemodynamic and / or vascular parameter values or hemodynamic or vascular response to the stimulus previously measured in a region of interest of the arteriole zone or ACT zone, preferably in the human subject brain, preferably wherein said vascular parameter value is selected among vessel diameter, vessel length and vessel tortuosity and hemodynamic parameter values is selected among: blood velocity, blood flow, blood pressure and blood volume;

[0115] ii) comparing said set of parameters to corresponding control value(s),

[0116] iii) concluding that said subject having received at least one dose of therapeutic agent is likely responsive to said treatment from said at least one vascular and said least one vascular and at least one hemodynamic phenotype change compared to corresponding control value(s).

[0117] The method for evaluating therapeutic response according to the present disclosure can indicate success or failure of a subject’s treatment.

[0118] In a preferred embodiment, the present disclosure relates to a non-invasive method for evaluating the therapeutic response to a TGFp agonist in a human subject suffering from a disease, preferably a neurological disease associated with mural cell dysfunction comprising: determining at least one vascular and / or at least one hemodynamic phenotype change in a region of interest in the arteriole zone or ACT zone, preferably in the brain in a human subject compared to corresponding control value(s), preferably wherein said vascular and / or hemodynamic phenotype change is determined by comparing at least one vascular parameter value and / or at least one hemodynamic parameter, previously measured in a region of interest in the arteriole zone or ACT zone, with corresponding control value(s) and preferably wherein said vascular parameter value is selected among vessel diameter, vessel length and vessel tortuosity and said hemodynamic parameter values is selected among: blood velocity, blood flow, blood pressure and blood volume, and wherein a lower vessel tortuosity compared to corresponding control value(s), is indicative that the human subject is likely responsive to TGFP agonist treatment.In a more preferred embodiment, the method as described in the previous paragraph, further comprise determining or computing neurovascular coupling, by determining at least one vascular and / or at least one hemodynamic phenotype change in response to a stimulus, preferably nervous stimulus compared to corresponding control value(s), in a region of interest in the arteriole zone or ACT zone, preferably in the brain in a human subject, wherein a lower neurovascular coupling compared to corresponding control value(s), is indicative that the human subject is likely responsive to TGFP agonist treatment.

[0119] In another preferred embodiment, the present disclosure relates to a non-invasive method for evaluating the therapeutic response to an Akt inhibitor in a human subject suffering from a disease, preferably a neurological disease associated with mural cell dysfunction comprising: determining at least one vascular and / or at least one hemodynamic phenotype change in a region of interest in the arteriole zone or ACT zone, preferably in the brain in a human subject compared to corresponding control value(s), preferably wherein said vascular and hemodynamic phenotype change is determined by comparing at least one vascular parameter value and at least one hemodynamic parameter value, previously measured in a region of interest in the arteriole zone or ACT zone, to corresponding control value(s), and preferably wherein said vascularis selected among vessel diameter, vessel length and vessel tortuosity and hemodynamic parameter values is selected among: blood velocity, blood flow, blood pressure and blood volume, and wherein a lower vessel tortuosity, lower vessel diameter and / or higher blood velocity compared to corresponding control value(s), is indicative that the human subject is likely responsive to Akt inhibitor treatment.

[0120] In another particular embodiment, the present disclosure relates to the therapeutic use of a therapeutic agent in a human subject suffering from a disease, preferably a neurological disease associated with mural cell dysfunction as described above, wherein said therapeutic agent is readministered to said human subject after the patient has been administered with at least one dose of said therapeutic agent and when said patient is evaluated as likely responsive to said therapeutic agent in a method as described above.

[0121] The present disclosure relates to a method for treating a disease, preferably a neurological disease associated with a mural cell dysfunction as described above in a human subject in need thereof comprising:i) determining at least one vascular and / or at least one hemodynamic phenotype change in a region of interest in the arteriole zone or arteriole-capillary transition (ACT) zone, preferably in the brain in said human subject compared to corresponding control value(s), wherein said vascular and / or hemodynamic phenotype change is determined by comparing at least one vascular parameter value and / or at least one hemodynamic parameter value in a region of interest of the arteriole zone or ACT zone of the human subject with corresponding control value(s), wherein said vascular parameter value is selected among vessel diameter, vessel length and vessel tortuosity and said hemodynamic parameter value is selected among: blood velocity, blood flow, blood pressure and blood volume,

[0122] wherein at least one vascular and / or at least one hemodynamic phenotype change compared to corresponding control value(s) is indicative that said subject is likely responsive to said therapeutic agent,

[0123] ii) re-administering to said subject who has been evaluated as likely responsive to said therapeutic agent, a therapeutically effective amount of said therapeutic agent.

[0124] In a particular embodiment, the present disclosure relates to to a method for treating a disease, preferably a neurological disease associated with a mural cell dysfunction as described above in a human subject in need thereof comprising:

[0125] iii) incorporating in a software a set of parameters comprising the hemodynamic and / or vascular parameter values or hemodynamic or vascular response to the stimulus previously measured in a region of interest of the arteriole zone or ACT zone, preferably in the human subject brain, preferably wherein said vascular parameter value is selected among vessel diameter, vessel length and vessel tortuosity and hemodynamic parameter values is selected among: blood velocity, blood flow, blood pressure and blood volume;

[0126] iv) comparing said set of parameters to corresponding control value(s),

[0127] v) concluding that said subject having received at least one dose of therapeutic agent is likely responsive to said treatment from said at least one vascular and said least one vascular and at least one hemodynamic phenotype change compared to corresponding control value(s),

[0128] vi) re-administering to said subject who has been evaluated as likely responsive to said therapeutic agent, a therapeutically effective amount of said therapeutic agent.Therapeutic agent that can be used according to the present method are as non-limiting examples : anti-angiogenic drug, anti-inflammatory drug or mural cell targeting drug, Immunomodulatory imide drugs (IMiDs) or Rho signalling inhibitors as described in previous section.

[0129] The present disclosure also relates to the use of therapeutic agent in the manufacture of a medicament for the treatment of disease, preferably a neurological disease associated with a mural cell dysfunction in a human subject in need thereof wherein said therapeutic agent is administered to said human subject after the patient has been administered with at least one dose of said therapeutic agent and when said patient is evaluated as likely responsive to said therapeutic agent in a method as described above.

[0130] The present disclosure also relates to a pharmaceutical composition comprising a therapeutic agent as described above for use in the treatment of of disease, preferably a neurological disease associated with a mural cell dysfunction as described above in a human subject in need thereof, preferably wherein said pharmaceutical composition is administered to said human subject after the patient has been administered with at least one dose of said therapeutic agent and when said patient is evaluated as likely responsive to said therapeutic agent in a method as described above. Said pharmaceutical composition may comprise a therapeutic agent selected from the group consisting of: anti-angiogenic agent; anti-inflammatory agent, mural cell targeting drug, Immunomodulatory imide drugs (IMiDs) or Rho signalling inhibitors as described in previous section. Said pharmaceutical composition can comprise one or more pharmaceutical acceptable excipient, diluent or carrier as described above

[0131] The composition may be administered by any means known to those skilled in the art, including, without limitation, intravenously, orally, intra-tumoral, intra-lesional, intradermal, topical, intraperitoneal, intramuscular, parenteral, subcutaneous and topical administration. Thus, the composition may be formulated as an injectable, topical, or ingestible formulation. Administration of the composition to a subject in accordance with the present disclosure may exhibit beneficial effects in a dose-dependent manner. Thus, within broad limits, administration of larger quantities of the composition is expected to achieve increased beneficial biological effects than administration of a smaller amount. Moreover, efficacy is also contemplated at dosages below the level at which toxicity is seen.It will be appreciated that the specific dosage of an administered in any given case will be adjusted in accordance with the composition being administered, the volume of the composition that can be effectively delivered to the site of administration, the disease to be treated or inhibited, the condition of the subject, and other relevant medical factors that may modify the activity of the compositions or the response of the subject, as is well known by those skilled in the art.

[0132] For example, the specific dose of composition for a particular subject depends on age, body weight, general state of health, diet, the timing and mode of administration, the rate of excretion, medicaments used in combination and the severity of the particular disorder to which the therapy is applied. Dosages for a given patient can be determined using conventional considerations, e.g., by customary comparison of the differential activities of the immunotherapy and pharmaceutical compositions described herein and of a known agent, such as by means of an appropriate conventional pharmacological protocol. The composition can be given in a single dose schedule, or in a multiple dose schedule.

[0133] EXAMPLES

[0134] A. Eng-iKOe mice

[0135] 1. Methods

[0136] 1.1 Mice and tissue

[0137] This study was performed in compliance with the French and Dutch government guidelines and the directive 2010 / 63 / EU of the European Parliament. All efforts were made to minimize the number of animals used and their suffering. The institutional Committees for Animal Welfare of He de France and Leiden University Medical Centre (project numbers 2014-19 2041.01 and AVD1160020174065, respectively) approved all protocols. Cdh5(PAC)-CREERT2,' Er mice were provided by Prof. HM. Arthur (Biosciences Institute, Faculty of medical Sciences, Newcastle University, UK). Cdh5(PAC)-CREERT2; Engf / fmice were also bred with the NG2DsRedBAC strain that has mural cells labelled in red to generate Cdh5(PAC)-CREERT2En^d;NG2DsRedBAC mice.

[0138] Mice were of either gender and used at 8-12 weeks of age. They received tamoxifen (2.5 mg per day, total volume 50 pL per injection) by intraperitoneal injection for 5 consecutive days todeplete endoglin in endothelial cells. Tamoxifen was purchased from Sigma-Aldrich, (cat. number T5648) and dissolved in 1:4 ethanol (Merck, cat. number 107017) and corn oil (Sigma-Aldrich, cat. number C8267) vehicle. Animals were subsequently harvested on day 9.

[0139] Intraperitoneal injection of either the vehicle (DMSO or PBS), C381 (10 mg.kg-1 of animal body weight, volume 50 pL) or VAD044 (5mg.kg-l of animal body weight, volume 50 pL) was administrated to Eng- / A7cmice for two consecutive days. Injections started on day 2 after gene deletion. Control animals received vehicle alone. Animals were subsequently harvested on day 9.

[0140] The Contrast agent used for fULM experiments (Sonovue Bracco, reconstructed in 0.3 mL saline) was injected intravenously in the tail of the mouse by a push syringe (KD Scientific) leading to a continuous injection at 800 pL.h'1rate. The highest injection volume allowed by international recommendations for a mouse of 25 g is 0.62 mL (Diehl, K. H. et al. J Appl Toxicol 21, 15-23 (2001), Morton, D. B. et al. Lab Anim 35, 1-41 (2001)). Here, the injection of less than 0.4 mL corresponded to a maximum 22% change in a total blood volume of 1.8 mL. The MB solution was manually mixed in the syringe during the resting time interval by waving a magnet inside to ensure the temporal stability of the number of MBs that were injected. Facial left whiskers of mice were brushed manually at a 2 Hz frequency to create local hyperaemia in the somatosensory cortex. The whisker stimulation protocol included 30 s of rest, 30 s of stimulation, and 10 s of rest. This pattern was repeated 25 times for fULM acquisitions. Results in Figure 8 b-d were achieved by employing a final pattern with a 10 s duration of stimulation aiming at emphazing the early response in the Power Doppler Signal. A fUS acquisition was conducted during 3 stimulation patterns prior to the start of each fULM experiment in order to confirm the haemodynamic response to whisker brushing.

[0141] For fUS experiments, the whisker stimulation protocol included 50 s of rest and 10 s of stimulation or 30 s of rest and 30 s of stimulation. These patterns were repeated 10 times. To analyse the retinal vasculature, adult mice were sacrificed and eyes were removed and prefixed in 4% paraformaldehyde (PF A) in PBS for 10 min at room temperature. The inventors dissected the retinas and post-fixed them in 4% PFA in PBS overnight and then processed for immunohistochemistry as described23.Mouse brains were collected in physiological salt, fixed overnight in 0.2% paraformaldehyde in 0.1 M phosphate buffer with 0.12 M CaC12 and 4% sucrose and then processed as described in Lebrin, F. et al. Nat Med 16, 420-428 (2010). The inventors used 25 mm sections for staining.

[0142] 1.2 Immunofluorescence staining

[0143] Whole-mount immunofluorescence staining of retinas was as previously described (Lebrin, F. et al. Nat Med 16, 420-428 (2010)). Biotinylated Griffonia simplicifolia lectin (isolectin B4) (B-1205, Vector Laboratories, 1:50) combined with streptavidin Cy-5 (PA45001, Sigma-Aldrich, 1:100) was used to stain endothelial cells, rat anti-mouse endoglin (120401, BioLegends, 1:100) combined with donkey anti-rat Alexa 488 (A-21208, Invitrogen, 1:250) was used to check endoglin deletion. FITC conjugated anti-a Smooth Muscle Actin (SMA) (clone 1A4) (F3777, Sigma-Aldrich, 1:100) was used to stain SMCs.

[0144] Frozen sections of the brain were fixed in cold acetone for 10 min and then washed with PBS. They were permeabilised with 0.2% Triton X-100 (0694, VWR) for 5 min at room temperature (RT) and then blocked for 2 h at RT with blocking solution (PBS pH 7.4, Triton-XlOO 0.1%, chicken serum 5%). Primary antibodies were used in PBS with 2% Bovine Serum Albumin (BSA) (A9418, Sigma) and included rat anti-mouse endoglin (120401, BioLegends, 1:100) to stain endothelial cells and validate endoglin deletion, FITC conjugated anti-a Smooth Muscle Actin (SMA) (clone 1A4) (F3777, Sigma-Aldrich, 1:100) to stain SMC and goat anti-mouse aminopeptidase N / ANPEP (cdl3) (R&D systems, AF2335, 1:100) to stain pericytes. After washing with PBS, sections were incubated for 2h at RT with secondary antibodies diluted in blocking buffer. The secondary antibodies used were donkey anti-rat Alexa 488 (A-21208, Invitrogen, 1:250) and donkey anti-goat Alexa 555 (A-21432, Invitrogen, 1:250). Endothelial cells were labelled with Biotinylated Griffonia simplicifolia lectin (isolectin B4) (B-1205, Vector Laboratories, 1:50) as described (Lebrin, F. et al. Nat Med 16, 420-428 (2010)) before mounting the sections with DAKO mounting medium (S3023, Dako).

[0145] 1.3 Transmission Electron Microscopy (TEM)

[0146] Isolated retinas were incubated in fixative buffer 1 (0.1 M sodium-cacodylate buffered solution, pH 7.4 with glutaraldehyde 2.5% and PFA2%) (16210, 15710, Electron Microscopy Sciences) for 1.5 h at RT. They were subsequently rinsed twice with 0.1 M sodium cacodylate-buffered solution, and post-fixed in fixative buffer 2 (1% osmium tetroxide and 1.5% potassium ferrocyanide in 0.1 M sodium cacodylate) for 1 h on ice. Retinas were washed twice withdemineralised water and then rinsed twice with ethanol 70%. Subsequently, retinas were dehydrated overnight in ethanol 70%, and incubated sequentially in ethanol 80%, 90% (10 min each step) and 100% (2 steps of 15 min and 1 step of 30 min).

[0147] Tissues were infiltrated with mixtures of Epon LX-112 (21210, Ladd Research Industries) at concentrations of 25%, 50%, and then 75% in anhydrous acetone for 30 min. Subsequently, they were infiltrated with pure Epon LX-112 for 2 h, with 1.5 h at RT, and the last 30 min at 60°C. Next, the samples were mounted in BEEM flat embedding moulds (AGG3654, Agar Scientific Ltd), embedded in Epon LX-112, and polymerised for 48 h at 60°C.

[0148] Ultrathin sections of 100 nm were cut using a diamond knife (Diatome Ltd) and collected on single slot copper grids (G2010-Cu, Sciences Services) covered with a formvar film and carbon layer. Sections were post-stained with an aqueous solution of 7% uranyl acetate for 20 min, followed by Reynold’s lead citrate for 10 min. Imaging was performed at an acceleration voltage of 120 kV using a Tecnai G2 Spirit BioTWIN TEM (Thermo Fisher Scientific), equipped with a FEI 4k Eagle CCD camera or on a FEI Tecnai G2 12 TWIN electron microscope, equipped with a Gatan OneView camera (Gatan, Pleasanton, CA). Image mosaics were recorded with binning 2 at 6500x or 6800x magnification, corresponding to a 3.4 nm and 3.25 nm pixel size at the specimen level. Data were collected and stitched together using automated acquisition and stitching software (Faas, F. G. et al. J Cell Biol 198, 457-469 (2012)). Virtual slides were analysed using Aperio ImageScope viewing software version 12.4 (Leica Biosystems).

[0149] 1.4 Morphometry and quantitative analysis

[0150] Complete high-resolution 3D rendering of whole mount retinas, and brain were acquired using a laser Scanning Microscope SP5 (Leica).

[0151] For the retinal vascular network, vessel length, diameter and branch points were manually quantified using Image J software (US National Institute of Health) in 4 fields per retina of 2.4 mm2, as described in Lebrin, F. et al. Nat Med 16, 420-428 (2010).

[0152] For pericyte detachment from the endothelium, as previously described in Grant, R. I. et al. J Cereb Blood Flow Metab 39, 411-425 (2019), the inventors analysed / characterised three types of mural cells in NG2DsRedBAC retinas: Ensheating Pericytes (EPs) on proximal branches of the arteriole zone, which covered most of the endothelium, pericytes that display mesh (MPs) with processes which extensively covered the capillary segments but did not exhibit the regularrepeating banding pattern of EPs and Thin-Strand processes (TSPs) in the capillary bed that possessed long, thin processes. All pericyte subtypes had a clear protruding ovoid soma. The inventors analysed 2D, average-projected confocal images of individual pericytes. Image J software (US National Institute of Health) was used to measure the roundness of the pericyte cell body. Roundness formula was given as = 4 x area / (7t x sqr(major axis). A minimum of 46 pericytes were analysed in at least 3 mice.

[0153] Quantification of smooth muscle cell coverage was performed using Imaged software by dividing the colocalised smooth muscle cell area and the IB4-stained area by the total IB4-stained area.

[0154] 1.5 Vessel permeability assay

[0155] Lysine-fixable cadaverine conjugated to Alexa Fluor-555 (500 mg for 20 g of mouse body weight) (Invitrogen), was injected intravenously into the tail vein in adult mice as described in Armulik, A. et al. Nature 468, 557-561 (2010). For in situ detection, animals were perfused for 1-2 min with HEPES saline buffer followed by 5 min perfusion with 4% PFA in PBS, pH 7.2. Retinas were dissected and then immunostained with Biotinylated Griffonia simplicifolia lectin (isolectin B4) (B-1205, Vector Laboratories, 1:50). Retinas were analysed by confocal microscopy (SP5, Leica).

[0156] 1.6 Ex-vivo retina electrostimulation

[0157] Whole retinas were mounted and maintained in an extracellular solution (NaCl 140 mM; Glucose 25 mM; KC1 5.5 mM; CaC12 1.8 mM; MgC12 1 mM; Hepes 10 mM; pH 7.3). Pericytes were stimulated by pressing the electrode filled with the same solution against the cell and by applying voltage pulse as described in Peppiatt, C. M., et al. Nature 443, 700-704 (2006). Resistance of the pipette was measured in order to define the input voltage (pulses 0.02 ms, 10 Hz for 5 s) to be applied to deliver a current intensity increasing from 1 to 3.5 pA. A total of 600 images were recorded in 2.5 min.

[0158] 1.7 Functional Ultrasound (fUS) acquisition

[0159] 1.7.1 Acquisition

[0160] Functional ultrasound imaging acquisitions were performed with a ID linear transducer (15 MHz central frequency, 128 elements, 110 pm spatial pitch) connected to a prototype functional ultrasound scanner (Iconeus One, Iconeus, Paris, France and Inserm ART Biomedical Ultrasound, Paris France). Data were acquired by emitting a group of 11 plane waves tiltedfrom -10° to +10°, fired at a 5.5 kHz pulse repetition frequency. The backscattered echoes of each group were summed to get compound images at 500 Hz framerate. Power Doppler images were computed from blocks of 200 compound images averaged after filtering with the Singular Value Decomposition (SVD) Spatio-temporal clutter filter (Demene, C. et al. Sci Transl Med 9 (2017)), removing the 60 first singular values to discard tissue motion. Each pixel of the final Power Doppler image was reconstructed on a 100 x 100 pm2pixel in the plane, and the slice thickness was approximately 300 pm.

[0161] 1.7.2 Analysis of the relative blood volume in activated areas

[0162] Initial activation maps were computed for each animal with a single-subject generalised linear model. The stimulus pattern presented above was convolved by a canonical Haemodynamic Response Function (HRF) and Statistical Parametric Maps (SPM) were generated for each scan. Data pre-processing consisted of simple linear detrending. The cerebral blood volume temporal response was then estimated from a region of interest (1.4 mm diameter) centred on the peak z-score of the activation map, which was always located within the somatosensory barrel cortex S1BF area. The Cerebral Blood Volume (CBV) curves were then normalised to the baseline. Mean relative CBV values were estimated from the DCBV curves at early onset (average between 36 and 44 s) and later during the stimulus (average between 44 and 60 s). The rise time of the responses was estimated from the duration taken to increase the DCBV from 20 to 90% of the peak DCBV values.

[0163] Data processing and analyses were performed using Matlab (MATLAB Release 2018a, The Math Works, Natick, Massachusetts, United States).

[0164] 1.8 Functional Ultrasound Localisation Microscopy (fULM)

[0165] 1.8.1 Acquisition protocol

[0166] The acquisition protocol was the same as the one used for functional ultrasound. The previous blocks of 200 frames acquired at 500 Hz were first processed to discriminate the tissue from the injected contrast agent by discarding the twenty first eigenvalues of SVD decomposition. Each frame was then spatially interpolated 6 times using a Lanczos interpolation kernel. The final spatial resolution chosen for rasterization was (probe spatial pitch / 16* / 16) respectively corresponding to (6.875 pm x 6.5 pm). MBs were identified as the most intense local maxima of the correlation with a typical point spread function (Gaussian spot). Only MBs resulting in a correlation value higher that 0.7 were kept for the next step of processing.A spatial second order polynomial fit was then used to identify the sub-pixel maxima localization corresponding to the centre of an individual MB. Absolute coordinates obtained were projected onto the grid chosen to be sixteen times smaller than the initial resolution. A classical particle tracking algorithm (https: / / github.com / tivenez / simpletracker) was employed to track the maxima positions at each time step. Various additional constraints were used: the maximum particle speed was set to 100 mm.s-1 and MBs needed to be detected at least on 5 successive tracks to avoid rejection. The successive positions of an individual MB were compared to the previous one to derive its velocity vector field.

[0167] After estimating each individual microbubble trajectory using the tracking algorithm, a spatial linear interpolation was performed along the track to fill in the pixels crossed by the bubble trajectory between two MB positions in successive frames. This ensures that each pixel along the track receives a value of 1, indicating the presence of the microbubble in that pixel at a specific moment during the experiment. For each pixel, the total number of microbubbles detected per second was then calculated by summing these presence values. This results in a quantitative estimate of MB flow, expressed in MB / px / sULM images

[0168] 1.8.2 Construction and data analysis

[0169] Dynamic MB count and velocity maps were computed by accumulating successive 2 s time windows of MB trajectories (no overlapping between windows) at each time step. If no bubble were detected in a pixel during this accumulation time, the speed was set to 0 for this time window. The square root of the density was displayed in Fig.2a-b in order to visually adjust the image dynamic range to the smallest vessels.

[0170] 1.8.3 Comparison of the MB velocity and MB flow in arterioles and venules

[0171] The averaged MB flow and speed images (Figure 2a-b) provided information about haemodynamics of vessels with a 6.5 pm resolution over a brain wide field of view, allowing multiple haemodynamic and functional quantifications. First, arterioles and venules from the upper right cortex were discriminated by analysing the sign of the speed vector in the z-axis. Arteries carried oxygen-rich blood deep into the brain at a positive speed along the z-axis, while venules flowed out of the brain at a negative speed along the z-axis.

[0172] For each vessel of the left cortex, manual measures of the speed and the number of MB detected at various depths were extracted, leveraged on a profile line orthogonal to the vessel. Measures from one representative control and Eng-iKOemice is shown in Figure 2. At least 10 vesselswere analysed and averaged per mouse in Figure 7f. The dispersion of speed values observed in each animal was linked to the distribution of sizes of the cortex’s brain vessels. Resulting mean flow and mean speed were compared at various depth in the cortex with a separation between venules and arteries.

[0173] 1.8.4 fULM data construction and spatial resolution estimation

[0174] Dynamic ULM images were built by accumulating 2 s of temporal frames; i.e. 5 blocks of 200 ultrasound compounded frame. This set of MB flow and velocity images corresponded to the ‘raw temporal ULM data’ that could be described under the form of a Matrix (Nx, Nz, Nt) with Nx = 2150 (14 mm of spatial extended along the probe axis transducer line with a 6.5 pm final resolution), Nz = 1386 (9 mm of spatial extended in depth) and Nt = 875 (30 min of acquisition with a 0.5 Hz acquisition rate with Nt = pattern duration (70 s) * number of pattern (25)). From this raw ULM data, a ‘pattern-averaged temporal ULM data’ matrix of size (Nx, Nz, Nt’) with Nt’ = pattern duration (70 s; 35 ULM images) built by accumulating the density and speed of the 25 patterns corresponding to the same time point within the temporal pattern as described in Renaudin, N. et al. Nat Methods 19, 1004-1012 (2022). A mean MB flow and Velocity dynamic mapping over the averaged stimulation pattern was built this way with one map every 2 s during the 70 s recombined stimulation pattern.

[0175] 1.8.5 Construction of activation maps in fULM

[0176] The acquisition dataset was split into two subsets, one corresponding to baseline periods (0 s to 30 s within each repeated stimulation pattern) and one corresponding to stimulation periods (30 s to 60 s within each repeated stimulation pattern). MB flow and velocity maps were computed for these two subsets. Maps shown in Figure 2a-b were the resulting baseline MB flow and velocity images.

[0177] Activation maps showing the local increase of MB during the whisker stimulation were computed as the difference of the baseline and activation density maps normalised by the baseline density.

[0178] Furthermore, the inventors displayed all raw trajectories of MB corresponding to accumulated 4 s time-windows before stimulation and during the activation pattern (Figure 5b). These so-called ‘MB tracks’ were superimposed on the cumulative activation map corresponding to the relative MB flow increase averaged from the start of the stimulation (t = 30 s) to the actual timewindow. This ‘raw track data’ visualization allowed to have more insight into how the activation starts in the barrel cortex with a clear initial appearance of new MB tracks in vessels surrounding the activated arteriole (30-34 s) and a progressive increase of MB tracks propagating to the upper layers of the cortex in the upcoming time windows (Figure 5b, 34-38 s, 38-42 s, 42-46 s, 54-58 s).

[0179] 1.8.6 Temporal analysis pipeline

[0180] ULM MB flow and velocity maps corresponding to each time step within the stimulation patterns were built first at 0.5 Hz. In order to avoid any potential bias due to global variations of MB injections, only the stimulation patterns occurring during stable global MB flow injection were chosen manually and used for the analysis. If the global variation of MB flow in the whole brain was more important than the variation due to the whisker stimulation, the current pattern was not taken into account for the reconstruction of the global averaged signal. Among the whole set of 25 stimulation patterns, a typical number of N= 20.9 ± 2.7 stimulation patterns were kept for the analysis for all animals.

[0181] In agreement with former results obtained using optical imaging (Rungta, R. L., et al. Neuron 99, 362-375 e364 (2018)), the relative increase of MB count was higher in the small vessels surrounding the arteriole than in the arteriole itself. To compare fULM responses to the whisker stimuli, an area with constant size was selected manually in the stimulated area of the right cortex corresponding to the somatosensorial S1BF area for each animal. In this region of interest, an automatic extraction of venules and arterioles was performed with a vessel filter (Vesselness 2D) to keep only penetrating vessels. Arterioles were then split in two distinct parts: an upper part ranging from 0 pm (taken as the distance from pial vessels) to 400 pm depth and a lower part ranging from 400 pm depth to the lowest part of the vessel.

[0182] The MB flow map was averaged spatially at each time step over all the points composing the region of interest. The temporal MB flow profile for this ROI was normalised by the baseline and was called “the activation signal”.

[0183] This signal was summed over the two groups (control and Eng-iKOemice) to build the activation signals of Figure 5c and 5f. The standard deviation of each time point was computed as the mean spatial standard error of all animals.

[0184] For both control and Eng-iKOeactivation signals, the MB flow activation measures at early stimulation times (30 to 40 s) and late response (40 to 60 s) were compared.1.8.7 Quantification of hemodynamic response recovery

[0185] To compare fULM activation signals to the whisker stimuli in the control group (N=ll), the Eng-iKOe(N=12) group and the C381-treated group (N=12) (Figure 8e), a region of interest was manually selected for each acquisition in the stimulated area of the right cortex corresponding to the somatosensorial S1BF. In each acquisition some temporal patterns were considered as not sufficiently correlated to the stimulation pattern and were not taken into account into the temporal averaging for MB Activation’s signal construction. For this purpose, the correlation of the arterioles MB Count signal in the selected region of interest was computed with the stimulation pattern and a threshold of 0.3 was chosen. To avoid the presence of nonstimulation related increase of MB Count into the averaged signal, the correlation of a nonstimulated area, selected in the contralateral cortex region was manually drawn and its average MB Count signal was extracted. Only patterns for which this correlation was between 0.5 and -0.5 were kept. Finally, only acquisitions whose MB Count activation signals averaged over the stimulation pattern reached a 10% increase were kept. The inventors built the final activation signal by averaging the MB Count signal of animals from each group (N=7 in Control group, N=10 in KO group and N=9 in SRI).

[0186] 1.8.8 Backscattering and evaluation of vessels’ tortuosity

[0187] The inventors estimated the amplitude of the signal backscattered by each microbubble after its insonification to build the backscattering ULM images obtained in Figure 3 following the methodology described in Renaudin, N., et al. Sci Rep 13, 11477 (2023). The average backscattering coefficient estimated for each pixel provided valuable information about the position of the MBs in the out-of-plane y-axis. These backscattering maps (Figure 3a-d) provided a new imaging parameter shown to be more suitable than MB flow maps to detect micro-vessels and to measure vessel diameters (Figure 3a). Such backscattering ULM images were built for each animal of the two groups.

[0188] Arteries longer than 0.5 mm were automatically selected within a square ROI of 4 mm2(8 + / -2 vessels per ROI, mean +- std) located in the cortex, either in the left or right hemisphere. For each selected artery only tracks longer than 0.1 mm were kept to quantify tortuosity. The angular variation of the speed vector field within each individual vessel was directly linked to the tortuosity of the latter. The inventors quantified the standard deviation of the angular distribution of the velocity vector field of some arteries in the upper right cortex of a controland an Eng-iKOeanimal, providing a new method for tortuosity assessment in cerebral brain vessels.

[0189] 1.9 Statistical analysis

[0190] The inventors performed statistical analyses with Prism-9 software (GraphPad) using the two-tailed, unpaired Student’s t test or one-way ANOVA for multiple comparisons. The inventors used Dunnett’s test for post hoc pairwise comparisons. Results are expressed as mean ± standard error of mean (SEM). P values are shown on the graphs.

[0191] 2. Results

[0192] 2.1 Endothelial Eng gene deletion alters contractile pericyte function of the ACT zone

[0193] The inventors administrated tamoxifen to three-month old Ct / A5-CreERT2; Eng"n(Eng-iKC , NG2DsRedBAC mice which have mural cells labelled in red and examined the retinal and brain vasculature at day four after gene deletion. Loss of endothelial endoglin protein was confirmed by immunofluorescence staining. The retinal blood vessels appeared unchanged in Eng-iKOemice resembling that of control animals with the three interconnected capillary layers remaining intact. No differences in vessel area, vessel length or branch points could be observed between control and Eng-iKOemice. The superficial plexus was composed of six major arteries and veins that branched into arterioles and venules that were connected to a capillary network in direct contact with the intermediate and deep layers. The arterial network showed regular coverage by smooth muscle cells (SMCs) that were circumferentially aligned and the expression of a-smooth muscle actin (a-SMA) remained intact in Eng-iKOemice. TEM failed to reveal any apparent abnormalities in the morphology of the SMCs and confirmed the intact coat of the distal arterioles.

[0194] In contrast, EPs and MPs of the ACT zone in Eng-iKOemice showed a more rounded soma with a limited number of circumferential processes enwrapping capillaries (0.35 a.u. ± 0.09 versus 0.44 a.u. ± 0.11 and 0.41 a.u. ± 0.10 versus 0.48 a.u. ± 0.14, respectively) (Figure Ib-c and figure le), despite both genotypes having a similar number of pericytes. Blood capillaries were also significantly enlarged at the EP or MP soma midline (7.48 pm ± 1.70 versus 9.19 pm ± 1.71 and 5.49 pm ± 1.14 versus 6.00 pm ± 0.90, respectively) confirming the partial detachment of EPs or MPs of the ACT zone (Figure Id and figure If), while the vascular density and the number of branch points were found to be identical between the genotypes.TEM analysis confirmed that pericytes in the superficial layer of Eng-iKOemice were poorly associated to the endothelium with an enlarged basement membrane with space between the two cell types in comparison to control mice (Figure 1g).

[0195] To assess whether the deletion of Eng in endothelial cells alters the ability of mural cells to regulate capillary diameter, the inventors stimulated retinal SMCs and pericytes electrically by applying a pipette on their soma to induce a vascular constriction (Peppiatt, C. M. et al. Nature 443, 700-704 (2006)). Electrical stimulation applied to all studied SMCs induced arteriolar constriction in both control and Eng-iKOemice, with current intensities ranging from 1 to 2.5 pA and mean intensities of 1.84 pA ± 0.29 and 1.87 pA ± 0.29, respectively. Electrical stimulation applied to EPs and MPs also induced capillary constriction. The required current intensities used to stimulate EPs were slightly lower than that used to stimulate MP responses ranging from 1 pA to 2 pA and from 1 pA to 2.5 pA, respectively (Figure Ih-j). It correlated with high and low to undetectable a-SMA content. In Eng-iKOemice, most EPs and MPs constricted capillaries only when high current intensities were applied to the soma, and some pericytes even did not respond at all. Mean intensities were 2.12 pA ± 0.29 for EPs and 2.41 pA ± 0.22 for MPs in Eng-iKOemice while they were 1.55 pA ± 0.31 for EPs and 1.76 pA ± 0.25 for MPs in control mice (Figure Ih-j) TSPs of the capillaries did not exhibit any morphological differences, the number of pericytes was unchanged and capillaries had normal diameters between the two genotypes. TSPs were insensitive to electrical stimuli. TEM images confirmed the tight association through direct contacts between endothelial cells and TSPs in both control and Eng-iKOemice. MPs and TSPs in the capillaries are known to play vital roles for blood-brain barrier (BBB) maintenance and small molecule transport (Armulik, A. et al. Nature 468, 557-561 (2010)).

[0196] To access this, the inventors injected Cadaverine Alexa Fluor-555 in the circulation and analysed potential extravasation into the retinal parenchyma. EP and MP detachment in Eng-iKOemice did not induce altered vessel permeability. They next examined the contractile functions of mural cells in Eng-iKOemice five weeks after gene deletion. The present findings revealed that both EP and MP phenotypes worsened, and all studied SMCs now required higher current of intensities to induce vessel constriction.

[0197] The general features of the retinal vasculature are structurally and functionally similar to those of the cerebral vasculature, although it exists a more extended arteriole to venule network in the retinal circulation (Mughal, A., et al. J Physiol 601, 889-901 (2023)). In the cortex, pialarteries branch into penetrating arterioles, both of which are covered by SMCs that extend to arteriolar segments (ACT zones) covered by EPs and MPs marking the beginning of the capillary network (Figure Ik). The inventors confirmed that pericytes in the ACT zones of penetrating arterioles were much more rounded in the cortex of Eng-iKOemice than in control animals (0.35 a.u. ± 0.09 versus 0.60 a.u. ± 0.17) (Figure 11-m).

[0198] These results establish that contractile pericytes in the ACT zone exhibit a significant sensitivity to the Endoglin gene deletion and furthermore, they indicate that mural cell detachment in both the arterial and ACT zones progresses over time potentially leading to blood flow dysregulation.

[0199] 2.2 fULM reveals rapid cerebral haemodynamic changes upon Eng gene deletion The capillary bed structure in the cerebral cortex area exhibits remarkable conservation between mice and humans (Ji, X. et al. Neuron 109, 1168-1187 el 113 (2021)). Both species feature a consistent branching pattern connecting the feeding arterioles to the draining veins. There are 3 to 4 diverging bifurcations wrapped with EPs and MPs, collectively referred to as the ACT zone followed by 3 to 4 converging bifurcations that connect to the draining venules. To assess hemodynamic parameters of the various vascular compartments with a brain-wide field of view at a microscopic resolution, the inventors injected a contrast agent under the form of microbubbles (MBs) into the blood circulation of control and Eng-iKOemice at day four after gene deletion. The flow of these MBs in the cerebral vasculature was evaluated transcranially using a high frequency ultrasonic probe. Ultrafast imaging using eleven compounded plane wave transmissions at a 5500 Hz pulse repetition frequency (PRF), enabled continuous ultrasound image acquisition at a high frame rate of 500 Hz. Singular value decomposition of consecutive blocks of 200 ultrasound images separated MB signatures from the tissue (Demene, C. et al. IEEE Trans Med Imaging 34, 2271-2285 (2015)). Localizing MBs in each image, tracking their trajectories both in space and time, and accumulating millions of them enabled the extraction of local density and velocity vector field images with a spatial resolution of 6.5 pm and with a temporal resolution of 2 s. During data acquisition, whiskers were intermittently brushed in short periods for 25 repetitions of 30 s whisker stimulations. These stimuli led to an increase in the number of MBs detected in this area, indicating enhanced local perfusion in response to neuronal activation (hyperaemia) (Renaudin, N. et al. Nat Methods 19, 1004-1012 (2022)). The inventors accumulated the positions and speeds of the MBs over the patterns and used temporal sliding windows on the previous set of images to construct dynamic maps of MB flow. This approach allowed us to differentiate MBs during resting and stimulation periodswithin the same acquisition, enabling the study of both basal haemodynamic and the brain- wide response to a whisker stimulus using the same animals. Baseline maps of MB flow were computed by counting MBs detected in each pixel during the rest periods, while velocity maps were computed as the mean velocity of these bubbles in each pixel during the rest periods. Two-dimensional (2D) maps of total MB count (Figure 2a) and average speed (Figure 2b) revealed most of the cerebral vascular organization with vessel diameters ranging from 70 pm down to 10 pm in both control and Eng-iKOemice. Arterioles and venules from the upper right cortex were discriminated by analysing the sign of the speed in the vertical z-axis. The inventors were able to decipher pial arteries, descending arterioles, down to 2nd-3rdorder blood capillaries and venules to ascending veins. They did not observe any major architectural vascular distinctions between both genotypes (Figure 2a-b). For each blood vessel, manual measures of the speed at various depths were then extracted from a profile line orthogonal to the vessel. Quantitative analyses of the MB flow and velocities showed that endoglin depletion did not alter the haemodynamic of the venous system when measured across the entire cortical depth in Eng-iK()em cQ (Figure 2c-d). In contrast, MB velocity was found to be decreased in the arterioles and ACT zones of the Eng-iKOemice (-13.9% and -23.0% compared to control mice, respectively) using fULM while MB flow remained unchanged, indicating a dilation of the descending arterioles and pre-capillary arterioles (Figure 2e-f). Interestingly, the phenotype of the descending arterioles was more pronounced in the deep layers of the cortex (ranging from 0.4 mm to 1.6 mm in depth) corresponding to ACT zones, where blood vessels are covered by EPs and MPs (Figure lk-1). Due to the large field of view of the present imaging modality, simultaneous analyses could be obtained for every descending arteriole and ascending vein and capillary across the whole mouse brain slice image. On average in the right cortex, the inventors analysed 15 descending arteries, 5 ascending veins and 25 lst / 2nd-order blood capillaries per animal confirming a general functional alteration of the arteriole and ACT blood vessels in Eng-iKOemice.

[0200] 2.3 Arterioles appear irregular in shape influencing fluid flux

[0201] To identify possible structural anomalies, the inventors extracted the additional backscattering information available in 2D fULM imaging (Renaudin, N., et al. Sci Rep 13, 11477 (2023)) (Figure 3a). The amplitude of the backscattered echoes of each MB was registered and its mean value was computed in every pixel of the image. This approach allowed for better delineation of small sized-blood vessels compared to conventional fULM imaging with a 3-dimensional (3D) rendering effect thanks to the intrinsic ability of the backscattering amplitude to conveyphysical information about the out-of-plane distance (Renaudin, N., et al. Sci Rep 13, 11477 (2023)). As expected, descending arterioles and the 1stto 3rdbranches in Eng-iKOemice exhibited larger diameters compared to the blood vessels of control animals (86.93 pm ± 22.01 versus 75.35 pm ± 17.65) at day four after gene deletion (Figure 3b). Furthermore, arterioles in Eng-iKOemice exhibited deformations, including twist and helical buckling vascular structures, in contrast to the normal straight cylindrical shape observed in control mice, indicating a loss of stability under mechanical stress (Figure 3a). In order to quantify this phenotype, the tortuosity of the descending arterioles was estimated using the variation of the velocity vector field’s orientation in vessels (Lowerison, M. R. et al. Sci Rep 12, 619 (2022)). This was particularly useful for identifying blood vessels with discrete irregular shape and tortuosity. As expected, descending arterioles had significantly higher metrics of tortuosity in Eng-iKOemice in comparison to control mice (Figure 3c-d). Moreover, helical buckling vascular structures were detected in deep brain regions of Eng-iKOemice, but never in control animals (Figure 3e).

[0202] 2.4 Functional ultrafast ultrasound (fUS) imaging reveals neurovascular coupling alterations

[0203] To access how EP and MP dysfunctions in the ACT zone impact the haemodynamic response to neuronal activity, the inventors first used fUS imaging in control and Eng-iKOemice at day four after gene deletion (Mace, E. et al. Nat Methods 8, 662-664 (2011), Rabut, C. et al. Nat Methods 16, 994-997 (2019)). The inventors applied a series of ten mechanical whisker stimulations, each lasting for 30 s, followed by a 40 s rest period. Each stimulation reliably generated a fUS power doppler signal detectable at the level of single voxels in both control and Eng-iKOemice, indicative of an increase in Cerebral Blood Volume (CBV) in the barrel cortex (Figure 4a-b). As expected, the baseline CBV measured before each stimulation was slightly higher in Eng-iKOemice compared to control mice. However, successive stimulations did not affect baseline levels ruling out the possibility that changes in baseline CBV overtime may influence the haemodynamic response to sensory stimulation (Figure 4c). In control mice, an initial overshoot was observed during stimulation before the signal settled to a new steadystate value and until the stimulation end. The inventors therefore separated the hemodynamic response into two phases: an early phase corresponding to the overshoot and a late phase representing the steady-state response (Figure 4d). Conversely, in Eng-iKOemice, no overshoot was detected (Figure 4d) and the initial response amplitude was lower compared tocontrol mice (11.70% ± 0.77 versus 9.28% ± 0.93) (Figure 4e). In contrast, the steady state amplitude response was similar in both control and Eng-iKOemice (Figure 4f). Additionally, the time to reach the maximal amplitude response was delayed compared to control mice (4.87 s ± 1.85 versus 7.15 s ± 1.73) (Figure 4g). The inventors also quantified the haemodynamic response at day one after gene deletion where there is no evidence of pericyte dysfunction. As anticipated, no differences in the amplitude response or in the rise time were observed between both genotypes confirming that EPs and MPs of the ACT zone play a regulatory function in the initiation of the haemodynamic response to neuronal activation.

[0204] 2.5 fULM reveals dysfunctions in the regulatory ACT zone during sensory stimulation

[0205] To gain insights into the spatial and temporal dynamics of functional hyperaemia in Eng-iKOemice, MBs detected during fULM acquisition were averaged within each spatial voxel (6.5 pm x 6.5 pm) and time window (2 s) and the results were then averaged over the twenty -five stimulation patterns. This process is analogous to block design processing in fMRI and resulted in the creation of a dynamic fULM movie that tracks the spatiotemporal hyperaemia during an averaged whisker stimulation pattern at microscopic scale (Figure 5a). During the early phase of stimulation (30-34 s), fULM revealed a significant activation (indicated by a relative increase in MB count) that was spatially localised around the arterioles, confirming the pivotal role of the ACT zones in the initiation of the hyperaemic response (Figure 5a).

[0206] This localised initial hyperaemia later extended from deep cortical regions to the cortical surface during sustained whisker stimulation (30-60 s) (Figure 5a). While this initial response amplitude was observed in the ACT areas deeply situated within the cortex and in the parenchyma surrounding the descending arterioles (corresponding to regions controlled by pericytes), there was relatively less activation detected within the arteriolar compartment driven by SMC. The representation of raw individual MB tracks detected in successive 4 s temporal windows during stimulation demonstrated an increase of MB detection events throughout the stimulation phases (Figure 5b). Neighbouring arteriolar compartments in the barrel cortex were not all activated (Figure 5a) emphasizing a plausible spatial optimization of the vascular network response (Schaeffer, S. & ladecola, C. NatNeurosci 24, 1198-1209 (2021)). The wide field-of-view offered by fULM compared to two-photon imaging enabled the examination of diverse responses in multiple distinct vascular compartments within a single experiment. The MB flow activation profile for arteriolar segments covered by SMC, located from the corticalsurface and down to 400 pm deep did not exhibit any significant difference between control and Eng-iKOemice (Figure 5c-e). Conversely, the same activation profile for the region located below depth z=400 pm that correspond to the ACT zones showed a lower initial response amplitude associated with a longer time to reach the maximal amplitude response in Eng-iKOemice compared to control animals (Figure 5f-h). The present findings revealed the spatial localisation of the altered vascular compartments and confirmed the selective dysfunction of the ACT zones using non-invasive ultrasound.

[0207] 2.6 Impaired active TGF-P bioavailability mediates pericyte dysfunction in Eng-iKO' mice

[0208] While HHT is currently recognised as a disease associated with reduced BMP9-10 / ALKl / Endoglin-mediated smadl / 5 signalling in endothelial cells rather than a disease of the TGF-P signalling as initially thought (Tillet, E. & Bailly, S. Front Genet 5, 456 (2014)), the question whether TGF-P plays a role in HHT remains elusive. The inventors isolated retinas from Eng-iKOemice at day four after gene deletion and treated them ex vivo with active BMP9 or TGF-pi for 3 h (Figure 6a). Subsequently, EPs were electrically stimulated to induce capillary constriction (Figure 6b-c). Pericytes of Eng-iKOemice, pre-incubated with TGF-P 1 but not with BMP9 constricted blood vessels at a mean intensity similar to control mice, thus restoring their contractile properties. Simultaneous incubation with actinomycin D, a potent inhibitor of transcription did not counteract the effects of TGF-P 1 in Eng-iKOeretinas. In contrast both SB431542 and Y27632, which inhibit ALK5 (activin receptor like kinase 5 also known as type 1 receptor for TGF-P) and Rock, respectively, blocked the effects of TGF-P 1 causing pericytes to induce vessel constriction with a mean intensity similar to untreated Eng-iKOeretinas (Figure 6b-c). The present findings revealed that impaired active TGF-P bioavailability in the intercellular space between endothelial cells and pericytes in Eng-iKOemice leads to reduced ALK5-mediated rock signalling in pericytes. This reduction is responsible for their partial detachment and inability to maintain proper blood vessel calibres (Figure 6d).

[0209] 2.7 fULM’s ability to differentiate the roles of VEGF-AKT and TGF-b pathways in Eng-iKCE mice

[0210] Restoration of TGF-P signalling would thus have therapeutic potential in HHT by improving blood vessel stability. To test this hypothesis, the inventors injected adult Eng-iKOemice with C381 for two consecutive days, starting at day 2 after gene deletion (Figure 7a). C381 has beenreported to induce TGF-P signalling in the brain and importantly to exhibit neuroprotective effects in various preclinical mouse models of neurodegenerative diseases. The neuroprotective properties of C381 are not fully understood but might depend on its potent anti-inflammatory properties (Vest, R. T. et al. Proc Natl Acad Sci U S A 119, e2121609119 (2022), Peppiatt, C. M., et al. Nature 443, 700-704 (2006)). C381 treatment was sufficient to preserve EP and MP attachment to the retinal blood vessels (Figure 7b). Electrical stimulation applied to EPs or MPs of Eng-iKOemice treated with C381 confirmed their ability to constrict blood capillaries with mean intensities similar to those applied to control mice (Figure 7c-d). However, C381 was more effective at preserving EPs than MPs (Figure 7b-d). Baseline maps of MB flow and velocity were generated during the resting period and the tortuosity of descending arterioles was measured as described (Figure 3c-d). While C381 treatment successfully prevented vessel tortuosity in Eng-iKOemice, it had no significant effect on the dilatation of the descending arterioles (Figure 7e-g). Increased Vascular Endothelial Growth Factor (VEGF)-phosphatidyl inositol 3-kinase / protein kinase B (Pi3K / AKT) signalling has been implicated in the development of HHT lesions (Jin, Y. et al. Nat Cell Biol 19, 639-652 (2017) ; Galaris, G. et al. Int J Mol Sci 22 (2021)). To explore this, the inventors tested VAD044, a novel AKT allosteric inhibitor currently in clinical trials for HHT. They found that VAD044 effectively prevented both blood vessel dilatation and vessel tortuosity in Eng-iKOemice (Figure 7e-g), but it was unable to restore pericyte attachment to the endothelium.

[0211] The inventors next investigated the haemodynamic changes induced by C381 during sensory stimulation. Although C381 treatment did not affect the baseline CBV (Figure 8a), C381-treated Eng-iKOemice exhibited an initial response similar to control mice. The treatment restored both the time to reach the peak and the amplitude of the response as assessed using both fUS (Figure 8b-d) and fULM (Figure 8e-f) technologies. The present findings reveal a novel property of C381 -its ability to restore pericyte attachment to the vessel wall by modulating TGF-b signalling in pericytes-. Importantly, the inventors demonstrate that transcranial fULM imaging effectively monitored this restored function.

[0212] Discussion

[0213] Although studies conducted in the last few years have shed considerable light on the cellular mechanisms controlling brain haemodynamic, the lack of imaging modalities capable of non-invasively visualizing discrete and fleeting events deep into organs at the micron scale level has limited the understanding on how the microcirculation continually adapts to respond tometabolic demands in both healthy and pathological conditions. Because diseases often start locally at the cellular level before expressing large scale and observable symptoms, the development of imaging modalities monitoring the whole brain vasculature and function down to micron scale resolution will not only benefit early diagnosis and treatment but will also support the development of future therapies targeting early cellular dysfunction.

[0214] Here, the inventors report that fULM can be applied non-invasively for evaluating structural and functional alterations of the microcirculation found in cerebral small vessel diseases such as HHT and at very early stage. The present results indicate that our fULM pipeline provides a unique method for assessing distinct vascular phenotypes across multiple dimensions, including the different vascular compartments along the arteriovenous axis, at baseline and during functional response to neuronal activation, the vascular architecture including diameter and tortuosity and under different therapeutic treatments. The present findings showcase the unique ability of non-invasive fULM to differentiate vascular phenotypes driven by distinct signalling pathways and vascular cells while effectively characterizing specific therapeutic effects (fig.

[0215] 8g). In this study, the advancement of fULM has been instrumental in elucidating the role of TGF-P in HHT, effectively resolving years of debate within the research community. Importantly, it has opened new avenues for the development of pericyte-focused therapies targeting TGF-P signalling.

[0216] Using HHT as a complex disease where a single gene deletion can alter multiple signalling pathways in both endothelial cells and pericytes, all of which contribute to the overall phenotype, The inventors show that deleting the Eng gene in endothelial cells led to a rapid detachment of a specific sub-population of pericytes located at the ACT zone.

[0217] At the molecular level, the inventors found that endoglin deletion in HHT resulted in impaired active TGF-P bioavailability within the intercellular space between endothelial cells and pericytes, which in turn affected their attachment, the arteriolar architecture and the haemodynamic during sensory stimulation. The present findings underscore that HHT is a condition with defects in BMP9 / 10 / ALKl / endoglin and VEGF signalling pathways in endothelial cells (David, L., et al. Blood 109, 1953-1961 (2007), Ricard, N. et al. Blood 119, 6162-6171 (2012), Larrivee, B. et al. Dev Cell 22, 489-500 (2012)), and altered TGF-P signalling in pericytes. VAD044 treatment that target AKT activity prevented blood vessel dilatation and tortuosity while it was unable to enhance pericyte attachment. In contrast, the inventors found that treatment with C381, a potent activator of TGF-P signalling significantlyrestored both pericyte coverage of the microvasculature, arteriole tortuosity and the cortical neurovascular coupling response in Eng-iKOemice. C381 is a first-in-class small molecule TGF-P activator that has shown therapeutic potential to ameliorate disease in models of neurodegeneration. While the anti-inflammatory and neuroprotective properties of C381 have already been demonstrated, notably its ability to restore lysosomal function (Vest, R. T. et al. Proc Natl Acad Sci U S A 119, e2121609119 (2022)), the inventors provide proof-of-concept data showing that C381 might also exhibit neuroprotective effects by targeting pericytes. Recently, transcranial ULM has been demonstrated in humans for non-invasive angiography at microscopic scales (Demene, C. et al. Nat Biomed Eng 5, 219-228 (2021)). This renders credible the clinical translation of fULM for monitoring cerebral vascular function during the treatment of HHT and other pericyte-related diseases. To accommodate transcranial imaging in humans, the ultrasonic frequency must be decreased from 15 MHz used in rodents to 6 MHz for transfontanellar imaging in human neonates, and 2 MHz for transcranial imaging in adult humans. The adult temporal bone serves as an acceptable acoustic window for transcranial imaging at this lower frequency, and microbubble backscattered echoes can be easily detected. Additionally, microbubble contrast agents are routinely employed in neurosonology to image challenging patients in several European countries and the USA. The accepted injection volume for clinical contrast imaging has been shown to be sufficient for producing high-resolution images of cerebral microvasculature in the first clinical trial of ULM technology (Rabut C. et al. Sci Transl Med. 2024 May 29;16(749):eadj3143). The ultrasonic amplitudes and acquisition durations utilized in this study were carefully selected to comply with safety regulations for diagnostic imaging, including the Mechanical Index, Spatial Peak Temporal Average Intensity, and Thermal Index. For clinical ULM, intravenous injections were performed using a bolus method; however, this should be adapted to a continuous infusion for functional ULM imaging to ensure stable microbubble concentrations during functional activations.

[0218] B. RVCL-S KI mice

[0219] 1. Methods

[0220] 1.1 Animals

[0221] Animal studies were performed using in-house generated transgenic homozygous Retinal Vasculopathy with Cerebral Leukoencephalopathy and systemic manifestations (RVCL-S) KI and wild-type (WT) littermate mice of different age groups (3-6, 6-9, 9-13, 15> months). These mice express the truncated protein resulted by the frameshift mutation at amino acid position235 of the Trexl protein on a C57B1 / 6 background as previously described (Mulder et al., Stroke; 2020 Jan;51(l):300-3072020). Animals were housed in pathogen-free mouse facilities with a temperature-controlled environment and ad libitum access to food and water. For both in vivo and ex vivo experiments as well as pathological analysis were performed on homozygous RVCL-S KI mice of both sexes, age matched with littermate controls mice. Animals were randomized for all experiments including age. Homozygous RVCL-S KI mice from 12 months of age, possibly develop age-related discomfort related to the expected RVCL-S disease progress. Bi-weekly welfare checks were performed of all mice above 12 months of age. These checks consisted of judging possible discomfort by assessing the increase of size of abdomen, body condition score, performing natural behavior, and mouse grimace. Additionally, once a week the welfare check also consisted of assessing the body weight.

[0222] For ex vivo analysis of the retina, mice of all age groups were euthanized via cervical dislocation to collect both eyes for path-clamp recordings of pericytes. In addition, brains were removed for pathological investigation. After removal, brains were fixed overnight in 0.2% paraformaldehyde (PF A) in 0.1 M phosphate buffer (PB) with 0.12 M CaCh and 4% sucrose, followed by incubation in the PB buffer without PFA and PB buffer with 15% sucrose, both overnight at 4 °C. Brain were then embedded in 7.5% gelatin in PB buffer with 15% sucrose and frozen on dry ice. Until further processing of the brains, gelatin blocks were stored at -80 °C. For immunohistochemistry brains were sectioned with a cryostat with a thickness of 25pm. Approval for experiments was obtained from local and national ethical committees that conformed to the European Communities Council Directive (2010 / 63 / EU), and experiments were carried out following ARRIVE guidelines.

[0223] 1.2 Patch-clamp recordings of pericytes

[0224] Patch clamp experiments were performed as follows. Briefly, fresh mouse retinas were dissected, superfused with Hepes-buffered solution containing 140 mM NaCl, 25 mM glucose, 5.5 mM KC1, 1 mM MgC12, 1.8 mM CaC12 and 10 mM Hepes, and maintained at pH 7.3 at room temperature. Glass pipettes with a resistance of 8-10 MQ were filled with the same Hepes-buffered solution and used to stimulate pericytes by pressing the electrode against the soma to apply voltage pulses, (pulses 0.02 ms, 10 Hz for 5 seconds) and to deliver current intensities ranging from 1 to 3.5 pA. Resistance of the pipette was measured before each experiment in order to define the input voltage. Pericytes were stimulated by applying voltage pulses 20seconds after patch-clamping and the vascular constriction was recorded during 210 seconds with a total of 300 images taken.

[0225] 1.3 Intravenous injection of tracers and detection of injected tracers

[0226] Vascular permeability experiments were performed as follows. Briefly, Lysine-fixable cadaverine conjugated to Alexa Fluor-555 (5 mg. ml'1in saline) (Invitrogen, cat. number A30677) was injected intravenously into the tail vein in adult homozygous RVCL-S mice and littermate control mice. Circulation time was 2 hours for cadaverine Alexa Fluor-555. Animals were harvested through perfusion of 1 minute PBS follow by 5 minutes of 4% PFAfor fixation. Brains were processed as previously described. For whole-brain pictures, the quantity of Alexa Fluor-555 injected was 500 pg per 20 grams body weight.

[0227] 1.4 Immunofluorescence staining

[0228] Coronal cryosections (25 pm) were fixed in cold acetone for 10 minutes, then washed in PBS and incubated in blocking / permeabilization solution (1% Bovine Serum Albumin (BSA) purchased from Sigma-Aldrich, cat. number A9418, 0.5% TritonX-100 purchased from Sigma-Aldrich, cat. number T8787 in PBS) for 2 hours at room temperature, followed by incubation overnight at 4 °C in an antibody solution (1% chicken serum purchased from Sigma- Aldrich, cat. number C5405, 1% BSA, 0.1% TritonX-100, 0.5% TWEEN 20 purchased from Sigma-Aldrich cat. number 9005-64-5 in PBS) with primary antibodies. For determination of neuroinflammation a marker for microglia rabbit anti-Ibal (ionized calcium-binding adapter molecule 1, 019-19741, Wako, 1:500) was combined with rat anti-mouse CD68 (MC1957, BioRad, 1:200). Endothelial cells were labelled with rabbi-ant Glutl (07-1401, Millipore, 1:500) and to establish coverage of pericytes goat anti-aminopeptidase N (CD13, AF2335, R&D systems, 1:100) was used. Cryosections were subsequently incubated in the antibody solution with secondary antibodies for 2 hours at room temperature. The secondary antibodies used were donkey anti-rabbit Alexa 488 (A-21206, Invitrogen, 1:200) with either donkey anti -rat Alexa 555 (A-48270, Invitrogen, 1:200) or donkey anti -goat Alexa 555 (A-21432, Invitrogen, 1:200). Whereafter the sections mounted with DAKO mounting medium (S3023, Dako). All images were acquired with a Leica SP8 confocal microscope (Leica Microsystems). Images were adjusted for brightness and contrast using Imaged and are presented as maximum intensity projections.For mural cell coverage of brain microvasculature, the inventors determined colocalization of mural cell markers (CD 13 -positive pericytes, red) with blood vessels (Glut 1 -positive endothelial cells, capillaries, green) on similar images with a uniform threshold between experiments and analysed the data with the colocalization function of Image J to identify pixels that had fluorescence intensity in both mural cells (CD 13 -positive cells) and endothelial cell markers (Glut 1 -positive cells).

[0229] Phenotypic distinction of activated microglia and quantification. 25 pm maximal projection z-stacks were reconstructed and the number of activated CD68 / Iba-1 double positive microglia per mm2was determined as previously described using ImageJ software Cell Counter plugin analysis tool. Activated microglia were identified based on their dramatic morphological changes marked by increased soma size, less ramified processes and an increased number of CD68 positive vesicles compared to homeostatic microglia. In each animal, 6 randomly selected fields (388.74 x 388.74 pm) from the primary somatosensory barrel cortex and hippocampus were analysed in 3 nonadj acent sections (~ 250 pm apart).

[0230] 1.5 Functional Ultrasound (fUS) acquisition

[0231] Preparation for imaging

[0232] fUS imaging experiments are transcranial only hair was removed of the head before dropping echographic gel. Animals were anesthetized by an interperitoneal i.p. injection, consisting of medetomidine (Sedastart, 0.6 mg / kg) and ketamine (Anesketin, 60 mg / kg). During the imaging session, the animals body temperature was kept at 37°C using a heating pad.

[0233] Stimulation protocol

[0234] During fUS acquisition a hemodynamic response was created by brushing the whiskers pattern wise. The whisker stimulation protocol included 30 s of rest and 30 s of stimulation, this pattern was repeated 10 times.

[0235] Acquisition

[0236] Functional ultrasound imaging acquisitions were performed with a ID linear transducer (15 MHz central frequency, 128 elements, 110 spatial pitch) connected to a prototype functional ultrasound scanner (Iconeus One, Iconeus, Paris, France and Inserm ART Biomedical Ultrasound, Paris France). Data were acquired by emitting a group of 11 plane waves tilted from -10° to +10°, fired at a 5.5 kHz pulse repetition frequency. The backscattered echoes ofeach group were summed to get compound images at 500 Hz framerate. Power Doppler images were computed from blocks of 200 compound images averaged after filtering with the Singular Value Decomposition (SVD) Spatio-temporal clutter filter, removing the 60 first singular values to discard tissue motion. Each pixel of the final Power Doppler image was reconstructed on a 100 x 100 pm2pixel in the plane, and the slice thickness was approximately 300 pm. Relative blood volume in activated area analysis

[0237] Initial activation maps were computed for each animal with a single-subject generalized linear model. The stimulus pattern presented above was convolved by a canonical Haemodynamic Response Function (HRF) and Statistical Parametric Maps (SPM) were generated for each scan. Data pre-processing consisted of simple linear detrending. The cerebral blood volume temporal response was then estimated from a region of interest (1.4 mm diameter) centred on the peak z-score of the activation map, which was always located within the somatosensory barrel cortex S1BF area. The Cerebral Blood Volume (CBV) curves were then normalized to the baseline. Mean relative CBV values were estimated from the DCBV curves at early onset (average between 36 and 44 s) and later during the stimulus (average between 44 and 60 s). The rise time of the responses was estimated from the duration taken to increase the DCBV from 20 to 90% of the peak DCBV values.

[0238] Data processing and analyses were performed using Matlab (MATLAB Release 2018a, The MathWorks, Natick, Massachusetts, United States).

[0239] 1.6 Ultrasound Localisation Microscopy (ULM)

[0240] Surgical procedure and preparation for imaging

[0241] Under deep anesthesia, consisting of medetomidine (Sedastart, 0.6 mg / kg) and ketamine (Anesketin, 60 mg / kg) which given with a bolus intraperitoneal i.p. injection, a craniotomy (removal of the skull) was performed. Before incision of the skin lidocaine (HCL, lOmg / ml 1%) was administered subcutaneously s.c.. followed by removing a window above the somatosensory cortex (AP-1.0 / L-4.0 to AP-3.0 / L-4.0 from Bregma) enabling the scanning of the SB IF area. After removal of the skull, an IV catheter was placed for continuous microbubble (MB) (Sonovue Braco, reconstructed in 1 ml 0.9% saline, 2^108 microbubbles / ml) infusion using a push syringe (Havard pump, at a rate of 0.6 ml / h). During the surgical procedure and imaging session, the animals body temperature was kept at 37°C using a heating pad.Acquisition

[0242] The acquisition protocol was the same as the one used for functional ultrasound. The previous blocks of 200 frames acquired at 500 Hz were first processed to discriminate the tissue from the injected contrast agent by discarding the twenty first eigenvalues of SVD decomposition. Each frame was then spatially interpolated 6 times using a Lanczos interpolation kernel. The final spatial resolution chosen for rasterization was (probe spatial pitch / 16* z / 16) respectively corresponding to (6.875 pm x 6.5 pm). MBs were identified as the most intense local maxima of the correlation with a typical point spread function (Gaussian spot). Only MBs resulting in a correlation value higher that 0.7 were kept for the next step of processing.

[0243] A spatial second order polynomial fit was then used to identify the sub-pixel maxima localization corresponding to the centre of an individual MB. Absolute coordinates obtained were projected onto the grid chosen to be sixteen times smaller than the initial resolution. A classical particle tracking algorithm was employed to track the maxima positions at each time step. Various additional constraints were used: the maximum particle speed was set to 100 mm. s'1and MBs needed to be detected at least on 5 successive tracks to avoid rejection. The successive positions of an individual MB were compared to the previous one to derive its velocity vector field.

[0244] Finally, a spatial linear interpolation was used to fulfil pixels crossed by a bubble trajectory between the two MB positions in successive frames. Maps of MB count were finally computed by accumulating all MBs detected in one single pixel during the selected acquisition time; velocity maps and vector field velocities were computed as the mean velocity of the microbubbles detected in each pixel.

[0245] ULM images construction and data analysis

[0246] Dynamic MB count and velocity maps were computed by accumulating successive 2 s time windows of MB trajectories (no overlapping between windows) at each time step. If no bubble were detected in a pixel during this accumulation time, the speed was set to 0 for this time window. The square root of the density was displayed in order to visually adjust the image dynamic range to the smallest vessels.

[0247] MB Speed in arteriolesThe averaged MB speed images provided information about haemodynamics of vessels with a 6.5 pm resolution over a brain wide field of view, allowing multiple haemodynamic and functional quantifications. Arterioles from the upper right cortex were discriminated by analysing the sign of the speed vector in the z-axis. Arteries carried oxygen-rich blood deep into the brain at a positive speed along the z-axis. For each vessel of the left cortex, manual measures of the speed and the number of MB detected at various depths were extracted, leveraged on a profile line orthogonal to the vessel. Measures from the same group of mice were pulled together in order to increase the number of values. The dispersion of speed values observed in each animal was linked to the distribution of sizes of the cortex’s brain vessels. Resulting mean flow and mean speed were compared at various depth in the cortex with a separation between venules and arteries.

[0248] 2. Results

[0249] The inventors report that method according to the present disclosure can be applied non-invasively for evaluating structural and functional alterations of the microcirculation found in another mural cell dysfunction model, RVCL-S KI model (Figures 9 and 10).

Claims

CLAIMS1. A non-invasive method for detecting or monitoring mural cell dysfunction, said method comprising:determining at least one vascular or at least one hemodynamic phenotype change from at least one vascular parameter value or at least one hemodynamic parameter value previously measured in a region of interest in the arteriole zone or arteriole-capillary transition (ACT) zone, preferably in the brain, in a human subject compared to corresponding control value(s),and preferably wherein said vascular parameter value is selected among vessel diameter, vessel length and vessel tortuosity and hemodynamic parameter values is selected among: blood velocity, blood flow, blood pressure and blood volume;wherein said at least one vascular or said least one hemodynamic phenotype change compared to corresponding control value(s) is indicative that the human subject is likely to have mural cell dysfunction.

2. A non-invasive method for evaluating the therapeutic response to a therapeutic agent in a human subject suffering from a disease associated with mural cell dysfunction, preferably a neurological disease associated with mural cell dysfunction, comprising: determining at least one vascular or at least one hemodynamic phenotype change from at least one vascular parameter value or at least one hemodynamic parameter value previously measured in a region of interest in the arteriole zone or ACT zone, preferably in the brain, in a human subject compared to corresponding control value(s), preferably wherein said vascular parameter value is selected among vessel diameter, vessel length and vessel tortuosity and hemodynamic parameter values is selected among: blood velocity, blood flow, blood pressure and blood volume,wherein said at least one vascular or at least one hemodynamic phenotype change compared to corresponding control value(s), is indicative that the human subject having received at least one dose of therapeutic agent is likely responsive to said treatment.

3. The method according to claim 1 or 2 wherein said vascular or hemodynamic parameter value is previously measured using Ultrasound Localization Microscopy (ULM) orfunctional ultrasound (fUS) imaging, and preferably wherein a contrast agent is previously administered to said human subject, preferably by bolus or infusion injection.

4. The method according to anyone of claims 1 to 3 wherein said control value is the vascular or hemodynamic phenotypes determined in a region of interest in the arteriole zone or ACT zone in the same human subject at a previous time, preferably in the same region of interest in the arteriole zone or ACT zone.

5. The method according to any one of claims 1 to 4 wherein said control value is a predetermined value.

6. The method according to any one of claims 1 to 5 further comprising a step of determining a neurovascular coupling phenotype change by comparing at least one vascular or hemodynamic parameter value change, preferably blood volume, blood velocity, or blood flow change in response to a nervous stimulus, previously measured in a region of interest in the arteriole zone or ACT zone in the human subject, with corresponding control value(s).

7. The method according to claim 6, wherein the determination of the neurovascular coupling phenotype change, and the determination of the vascular or hemodynamic change are measured in a single acquisition step, preferably using ULM, more preferably using ULM and f(US) imaging.

8. The method according to anyone of claims 1 to 7, wherein said mural cell dysfunction is associated with hereditary disease, preferably selected from the group consisting of: Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), Cerebral Autosomal Recessive Arteriopathy with Subcortical infarcts and Leukoencephalopathy (CARASIL), HTRA1 -autosomal dominant disease, Col4-related autosomal disease such as Collagen 4A1 and collagen 4A2 microangiopathy, Cathepsin-A-related arteriopathy with strokes and leukoencephalopathy (CARASAL), Retinal Vasculopathy with Cerebral Leukoencephalopathy and systemic manifestations (RVCL-S), Hereditary Hemorrhagic Telangiectasia (HHT), Fabry’s disease, Mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS), Cerebral Amyloid Angiopathy(CAA), Homocystinuria recessive disease, Sickle Cell disease, Parkes Weber syndrome, and CM-AVM syndrome, more preferably Hereditary Hemorrhagic Telangiectasia (HHT) or wherein said mural cell dysfunction is associated with a non-genetic disease, preferably selected from the group consisting of: stroke, traumatic brain injury, migraine, epilepsy, spinal cord injury, diabetes, Huntington’s disease, Alzheimer’s disease, Parkinson’s disease, Radiation necrosis, Amyotrophic lateral sclerosis, Vascular dementia, and Wybur-Mason syndrome.

9. The method according to any one of claims 2 to 8, wherein the therapeutic response is evaluated throughout the course of said treatment for monitoring the therapeutic response over time.

10. The method according to any one of claims 2 to 9 wherein said therapeutic agent is an anti-inflammatory drug, preferably selected among: anti-angiogenic agent such as Angiopoietin 2 inhibitor, VEGF inhibitor, Tyrosine kinase inhibitor, PI3K inhibitor, AKT inhibitor, mTor inhibitor, MEK1 / 2 inhibitor; anti-inflammatory agent, such as Non-steroidal anti-inflammatory drugs (NS AID), MAPK inhibitor, TNF inhibitor; mural cell targeting drug such as TGFP agonist or PDGF inhibitor; Immunomodulatory imide drugs (IMiDs) and Rho signalling inhibitor.

11. The method according to any one of claims 2 to 10 wherein the therapeutic agent is a TGFP agonist, and a lower vessel tortuosity compared to corresponding control value(s), is indicative that the human subject is likely responsive to TGFP agonist treatment.

12. The method according to any one of claims 2 to 10 wherein the therapeutic agent is a Akt inhibitor and wherein a lower vessel tortuosity, lower vessel diameter and / or higher blood velocity compared to corresponding control value(s), is indicative that the human subject is likely responsive to Akt inhibitor treatment.

13. The method according to any one of claims 1, 3 to 8, wherein a higher vessel diameter, a higher vessel tortuosity or a lower blood velocity compared to corresponding control value in a region of interest in the arteriole zone or ACT zone is indicative that said subject has a mural dysfunction, preferably associated with a neurological disease, such as HHT.

14. A therapeutic agent for use in the treatment of a disease associated with a mural cell dysfunction, preferably a neurological disease associated with mural cell dysfunction, in a human subject in need thereof wherein said subject is previously identified as having a mural cell dysfunction by a method according to any one of claims 1, 3 to 8 or 13, or wherein said subject is previously evaluated as likely responsive to said therapeutic agent in a method according to any one of claims 2 to 12.

15. The therapeutic agent for use according to claim 14 wherein said therapeutic agent is an anti-angiogenic agent such as Angiopoietin 2 inhibitor, VEGF inhibitor, Tyrosine kinase inhibitor, PI3K inhibitor, AKT inhibitor, mTor inhibitor, MEK1 / 2 inhibitor; antiinflammatory agent, such as Non-steroidal anti-inflammatory drugs (NS AID), MAPK inhibitor, TNF inhibitor ; mural cell targeting drug such as TGFP agonist or PDGF inhibitor; Immunomodulatory imide drugs (IMiDs) or Rho signalling inhibitor.